{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": ["apoE4-165"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease [23085451] The lack of progress in this area is a significant concern given the high prevalence of AD and the need for effective treatments to improve outcomes for patients [7510447] While there have been some promising results in preclinical studies, the development of disease-modifying therapies remains a major challenge in the field of Alzheimer's research [20360050]", "pmids": ["23085451", "7510447", "20360050"], "pmid_titles": {"23085451": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "23085451", "15783264", "37902139", "37490245"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "23085451": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": ["apoE4-165"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease [23085451] The lack of progress in this area is a significant concern given the high prevalence of AD and the need for effective treatments to improve outcomes for patients [7510447] While there have been some promising results in preclinical studies, the development of disease-modifying therapies remains a major challenge in the field of Alzheimer's research [20360050]", "pmids": ["23085451", "7510447", "20360050"], "pmid_titles": {"23085451": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "23085451", "15783264", "37902139", "37490245"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "23085451": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": ["apoE4-165"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease [23085451] The lack of progress in this area is a significant concern given the high prevalence of AD and the need for effective treatments to improve outcomes for patients [7510447] While there have been some promising results in preclinical studies, the development of disease-modifying therapies remains a major challenge in the field of Alzheimer's research [20360050]", "pmids": ["23085451", "7510447", "20360050"], "pmid_titles": {"23085451": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "23085451", "15783264", "37902139", "37490245"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "23085451": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
{"id": "62004357c9dfcb9c09000015", "question": "Does \u03b1CGRP have amyloidogenic properties?", "answer": "In this work, we investigated the amyloidogenic profile of \u03b1CGRP, a 37-residue-long peptide hormone, utilizing both biophysical experimental techniques and Molecular Dynamics simulations [29501724] The \u03b1CGRP polymerization was found to be amyloidogenic, with the formation of amyloid fibrils and aggregates [32093040] This suggests that \u03b1CGRP may have potential as a therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's [20360050]", "pmids": ["29501724", "32093040", "20360050"], "pmid_titles": {"29501724": "(No title fetched)", "32093040": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["33023198", "29501724", "17662457", "23551149", "37905874", "19363993", "21624562", "20360050", "20826658", "15014128", "22122056", "21764791", "37264659", "29698650", "32093040", "28922609", "23293020", "23510020", "15649697", "17244848"], "topk_titles": {"33023198": "(No title fetched)", "29501724": "(No title fetched)", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "23551149": "(No title fetched)", "37905874": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21624562": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "22122056": "(No title fetched)", "21764791": "Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.", "37264659": "(No title fetched)", "29698650": "(No title fetched)", "32093040": "(No title fetched)", "28922609": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "23510020": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia."}, "gold_ideal": ["Yes. \u03b1CGRP, a 37-residue-long peptide hormone, is a novel amyloidogenic member of the CGRP family", "Yes, it has amyloidogenic properties. It is a member of the CGRP family."], "gold_exact": ["yes"]}
{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": ["apoE4-165"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease [23085451] The lack of progress in this area is a significant concern given the high prevalence of AD and the need for effective treatments to improve outcomes for patients [7510447] While there have been some promising results in preclinical studies, the development of disease-modifying therapies remains a major challenge in the field of Alzheimer's research [20360050]", "pmids": ["23085451", "7510447", "20360050"], "pmid_titles": {"23085451": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "23085451", "15783264", "37902139", "37490245"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "23085451": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
{"id": "62004357c9dfcb9c09000015", "question": "Does \u03b1CGRP have amyloidogenic properties?", "answer": "In this work, we investigated the amyloidogenic profile of \u03b1CGRP, a 37-residue-long peptide hormone, utilizing both biophysical experimental techniques and Molecular Dynamics simulations [29501724] The \u03b1CGRP polymerization was found to be amyloidogenic, with the formation of amyloid fibrils and aggregates [32093040] This suggests that \u03b1CGRP may have potential as a therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's [20360050]", "pmids": ["29501724", "32093040", "20360050"], "pmid_titles": {"29501724": "(No title fetched)", "32093040": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["33023198", "29501724", "17662457", "23551149", "37905874", "19363993", "21624562", "20360050", "20826658", "15014128", "22122056", "21764791", "37264659", "29698650", "32093040", "28922609", "23293020", "23510020", "15649697", "17244848"], "topk_titles": {"33023198": "(No title fetched)", "29501724": "(No title fetched)", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "23551149": "(No title fetched)", "37905874": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21624562": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "22122056": "(No title fetched)", "21764791": "Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.", "37264659": "(No title fetched)", "29698650": "(No title fetched)", "32093040": "(No title fetched)", "28922609": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "23510020": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia."}, "gold_ideal": ["Yes. \u03b1CGRP, a 37-residue-long peptide hormone, is a novel amyloidogenic member of the CGRP family", "Yes, it has amyloidogenic properties. It is a member of the CGRP family."], "gold_exact": ["yes"]}
{"id": "61fa941ec9dfcb9c09000005", "question": "Should Intepirdine be used for Alzheimer's disease?", "answer": "Yes, Intepirdine is not currently approved for use in treating Alzheimer's disease [20154508] The available evidence suggests that it does not affect the main neuropathological hallmarks of the disease, including senile plaques and neurofibrillar tangles [17182990] However, preclinical animal studies have shown that human anti-amyloid-beta immunization does not simply clear amyloid from the Alzheimer's disease brain, but reduces some of the neuronal alterations that characterize Alzheimer's disease [20360050]", "pmids": ["20154508", "17182990", "20360050"], "pmid_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["23334070", "10510805", "7510447", "23624169", "21624562", "18620875", "7579023", "24633805", "24983746", "21705182", "20360050", "20154508", "29441009", "17182990", "19164222", "37943150", "23527322", "35558050", "37490245", "37389302"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "23624169": "(No title fetched)", "21624562": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "24633805": "(No title fetched)", "24983746": "(No title fetched)", "21705182": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "29441009": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "35558050": "(No title fetched)", "37490245": "(No title fetched)", "37389302": "(No title fetched)"}, "gold_ideal": ["No. In a phase 3 clinical trial Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate Alzheimer's disease dementia patients."], "gold_exact": ["no"]}
{"id": "6402c910201352f04a00000c", "question": "Can losartan reduce brain atrophy in Alzheimer's disease?", "answer": "Question: Can losartan reduce brain atrophy in Alzheimer's disease? [34687634] : [12345678] INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [17883890] Interpretation: Losartan was well tolerated but not effective in reducing brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [23624169]", "pmids": ["34687634", "17883890", "23624169"], "pmid_titles": {"34687634": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23624169": "(No title fetched)"}, "topk_used": ["34687634", "25871773", "23624169", "17883890", "15649697", "23293020", "24633805", "21624562", "15783264", "19278690", "20929585", "21705182", "22536363", "2107926", "23597030", "20154508", "35558050", "24983746", "8237620", "18620875"], "topk_titles": {"34687634": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23624169": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24633805": "(No title fetched)", "21624562": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "21705182": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "35558050": "(No title fetched)", "24983746": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "gold_ideal": ["No. 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease."], "gold_exact": ["no"]}
{"id": "64040edf201352f04a000011", "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "answer": "Question: Based on clinical trial data, can semagacestat delay cognitive impairment for people at risk for Alzheimer's disease? [31738372] (each starts with PMID): [12345678] INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [34146512] [12345678] abstract abstract INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [17182990]", "pmids": ["31738372", "34146512", "17182990"], "pmid_titles": {"31738372": "(No title fetched)", "34146512": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment."}, "topk_used": ["34146512", "29507718", "15783264", "37943150", "20413854", "17182990", "29441009", "21971452", "31738372", "19585948", "31574510", "19278690", "21705182", "24983746", "22546352", "21905097", "36281662", "25203109", "16974109", "21996556"], "topk_titles": {"34146512": "(No title fetched)", "29507718": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "20413854": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "31738372": "(No title fetched)", "19585948": "Novel strategies for the prevention of dementia from Alzheimer's disease.", "31574510": "(No title fetched)", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "36281662": "(No title fetched)", "25203109": "(No title fetched)", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly."}, "gold_ideal": ["No. Pioglitazone did not delay the onset of mild cognitive impairment."], "gold_exact": ["no"]}
{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
{"id": "5e4b64516d0a277941000029", "question": "Is Semagacestat effective for Alzheimer's Disease?", "answer": "Yes, Semagacestat was found to be ineffective for Alzheimer's Disease in a recent negative efficacy study [26064192] The study included several biomarkers of the disease as well as safety outcomes, and the results were published in a peer-reviewed journal [23883379] While the study did not show a statistically significant improvement in cognitive status, patients receiving the higher dose experienced significant worsening of functional ability [23334070]", "pmids": ["26064192", "23883379", "23334070"], "pmid_titles": {"26064192": "(No title fetched)", "23883379": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["20154508", "27567808", "7510447", "24983746", "23883379", "15649697", "25871773", "23334070", "23624169", "22536363", "23785331", "7579023", "28978478", "21149978", "21971452", "23196551", "26064192", "21784350", "21501112", "20360050"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "23624169": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "23785331": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "28978478": "(No title fetched)", "21149978": "(No title fetched)", "21971452": "(No title fetched)", "23196551": "(No title fetched)", "26064192": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21501112": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "gold_ideal": ["No. In a placebo controlled clinical trial, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. The trial was terminated due to unexpected aggravation of cognitive deficits and side effects."], "gold_exact": ["no"]}
{"id": "6057bf0694d57fd879000031", "question": "What promotes amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells?", "answer": "Question: What is the role of apoE4 fragment apoE4-165 in promoting amyloid-peptide beta 42 (A\u03b242) accumulation in neuroblastoma cells? [27476701] : 1 [32183293] We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis [23293020]", "pmids": ["27476701", "32183293", "23293020"], "pmid_titles": {"27476701": "(No title fetched)", "32183293": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["27476701", "33513738", "23796662", "23293020", "32582833", "36281662", "21903360", "23528227", "36687366", "22203915", "37943150", "22110363", "19228370", "21206757", "25871773", "23378928", "20122289", "23536396", "19181896", "32183293"], "topk_titles": {"27476701": "(No title fetched)", "33513738": "(No title fetched)", "23796662": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "32582833": "(No title fetched)", "36281662": "(No title fetched)", "21903360": "(No title fetched)", "23528227": "(No title fetched)", "36687366": "(No title fetched)", "22203915": "(No title fetched)", "37943150": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "21206757": "Presenilin 2 is the predominant \u03b3-secretase in microglia and modulates cytokine release.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "23536396": "Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid.", "19181896": "(No title fetched)", "32183293": "(No title fetched)"}, "gold_ideal": ["The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4 is more susceptible to proteolysis than apoE2 and apoE3 isoforms and carboxyl-terminal truncated apoE4 forms have been found in AD patients' brain. A specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.", "The amyloid-peptide beta 42 (A\u03b242) accumulates in neuroblastoma cells due to a protein called apoE4-165, which is an apolipoprotein (APOE4). This protein is the most common protein responsible for late-onset Alzheimer disease."], "gold_exact": ["apoE4-165"]}
{"id": "6026754f1cb411341a0000c8", "question": "Should minocycline be used for mild Alzheimer disease?", "answer": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease [23085451] The lack of progress in this area is a significant concern given the high prevalence of AD and the need for effective treatments to improve outcomes for patients [7510447] While there have been some promising results in preclinical studies, the development of disease-modifying therapies remains a major challenge in the field of Alzheimer's research [20360050]", "pmids": ["23085451", "7510447", "20360050"], "pmid_titles": {"23085451": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["10510805", "31738372", "23334070", "20360050", "7510447", "37943150", "20154508", "21996556", "23624169", "29441009", "2107926", "21705182", "24983746", "23785331", "24633805", "35558050", "23085451", "15783264", "37902139", "37490245"], "topk_titles": {"10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "31738372": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "37943150": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "23785331": "(No title fetched)", "24633805": "(No title fetched)", "35558050": "(No title fetched)", "23085451": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37902139": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer disease during a 2-year period."], "gold_exact": ["no"]}
{"id": "602673e91cb411341a0000c7", "question": "Is Lanabecestat effective for Alzheimer's disease?", "answer": "Yes, Lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease as shown by the APECS and AMARANTH trials [33049114] The BACE inhibitor verubecestat failed to show any benefit, while the BACE inhibitor lanabecestat was associated with treatment-related adverse events [29719179]", "pmids": ["33049114", "29719179"], "pmid_titles": {"33049114": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["23624169", "15649697", "33049114", "7579023", "29719179", "7510447", "31764959", "20154508", "30970186", "29461065", "22536363", "29397980", "24983746", "25871773", "23883379", "27567808", "31423903", "37943150", "37490245", "23785331"], "topk_titles": {"23624169": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "29719179": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "31764959": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "29397980": "(No title fetched)", "24983746": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "27567808": "(No title fetched)", "31423903": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)", "23785331": "(No title fetched)"}, "gold_ideal": ["No. Treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline of Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "604915581cb411341a00016a", "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?", "answer": "Yes, YKL-40 is a promising candidate biomarker of glial inflammation in Alzheimer's disease [31794792] Recently, cerebrospinal fluid (CSF) YKL-40 levels were reported to be a significant predictor of cognitive decline and amnestic mild cognitive impairment (aMCI) in patients with Alzheimer's disease (AD) [17182990] These findings suggest that YKL-40 could be a valuable biomarker for early detection and monitoring of AD [32045356]", "pmids": ["31794792", "17182990", "32045356"], "pmid_titles": {"31794792": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "32045356": "(No title fetched)"}, "topk_used": ["31794792", "32045356", "19278690", "15783264", "24175175", "37943150", "8180825", "17182990", "37556728", "21705182", "21971452", "20929585", "29441009", "37490245", "22529838", "19164222", "36281662", "19881909", "21996556", "19324376"], "topk_titles": {"31794792": "(No title fetched)", "32045356": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24175175": "(No title fetched)", "37943150": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37556728": "(No title fetched)", "21705182": "(No title fetched)", "21971452": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "29441009": "(No title fetched)", "37490245": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "36281662": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection."}, "gold_ideal": ["Yes,\ncerebrospinal fluid (CSF) YKL-40 levels were reported to be a promising candidate biomarker of glial inflammation in Alzheimer's disease (AD)."], "gold_exact": ["yes"]}
{"id": "62004357c9dfcb9c09000015", "question": "Does \u03b1CGRP have amyloidogenic properties?", "answer": "In this work, we investigated the amyloidogenic profile of \u03b1CGRP, a 37-residue-long peptide hormone, utilizing both biophysical experimental techniques and Molecular Dynamics simulations [29501724] The \u03b1CGRP polymerization was found to be amyloidogenic, with the formation of amyloid fibrils and aggregates [32093040] This suggests that \u03b1CGRP may have potential as a therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's [20360050]", "pmids": ["29501724", "32093040", "20360050"], "pmid_titles": {"29501724": "(No title fetched)", "32093040": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["33023198", "29501724", "17662457", "23551149", "37905874", "19363993", "21624562", "20360050", "20826658", "15014128", "22122056", "21764791", "37264659", "29698650", "32093040", "28922609", "23293020", "23510020", "15649697", "17244848"], "topk_titles": {"33023198": "(No title fetched)", "29501724": "(No title fetched)", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "23551149": "(No title fetched)", "37905874": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21624562": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "22122056": "(No title fetched)", "21764791": "Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.", "37264659": "(No title fetched)", "29698650": "(No title fetched)", "32093040": "(No title fetched)", "28922609": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "23510020": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia."}, "gold_ideal": ["Yes. \u03b1CGRP, a 37-residue-long peptide hormone, is a novel amyloidogenic member of the CGRP family", "Yes, it has amyloidogenic properties. It is a member of the CGRP family."], "gold_exact": ["yes"]}
{"id": "61fa941ec9dfcb9c09000005", "question": "Should Intepirdine be used for Alzheimer's disease?", "answer": "Yes, Intepirdine is not currently approved for use in treating Alzheimer's disease [20154508] The available evidence suggests that it does not affect the main neuropathological hallmarks of the disease, including senile plaques and neurofibrillar tangles [17182990] However, preclinical animal studies have shown that human anti-amyloid-beta immunization does not simply clear amyloid from the Alzheimer's disease brain, but reduces some of the neuronal alterations that characterize Alzheimer's disease [20360050]", "pmids": ["20154508", "17182990", "20360050"], "pmid_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology."}, "topk_used": ["23334070", "10510805", "7510447", "23624169", "21624562", "18620875", "7579023", "24633805", "24983746", "21705182", "20360050", "20154508", "29441009", "17182990", "19164222", "37943150", "23527322", "35558050", "37490245", "37389302"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "23624169": "(No title fetched)", "21624562": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "24633805": "(No title fetched)", "24983746": "(No title fetched)", "21705182": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "29441009": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "35558050": "(No title fetched)", "37490245": "(No title fetched)", "37389302": "(No title fetched)"}, "gold_ideal": ["No. In a phase 3 clinical trial Intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate Alzheimer's disease dementia patients."], "gold_exact": ["no"]}
{"id": "6402c910201352f04a00000c", "question": "Can losartan reduce brain atrophy in Alzheimer's disease?", "answer": "Question: Can losartan reduce brain atrophy in Alzheimer's disease? [34687634] : [12345678] INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [17883890] Interpretation: Losartan was well tolerated but not effective in reducing brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease [23624169]", "pmids": ["34687634", "17883890", "23624169"], "pmid_titles": {"34687634": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23624169": "(No title fetched)"}, "topk_used": ["34687634", "25871773", "23624169", "17883890", "15649697", "23293020", "24633805", "21624562", "15783264", "19278690", "20929585", "21705182", "22536363", "2107926", "23597030", "20154508", "35558050", "24983746", "8237620", "18620875"], "topk_titles": {"34687634": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23624169": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24633805": "(No title fetched)", "21624562": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "21705182": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "35558050": "(No title fetched)", "24983746": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "gold_ideal": ["No. 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease."], "gold_exact": ["no"]}
{"id": "64040edf201352f04a000011", "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "answer": "Question: Based on clinical trial data, can semagacestat delay cognitive impairment for people at risk for Alzheimer's disease? [31738372] (each starts with PMID): [12345678] INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [34146512] [12345678] abstract abstract INTERPRETATION: Semagacestat did not delay the onset of mild cognitive impairment [17182990]", "pmids": ["31738372", "34146512", "17182990"], "pmid_titles": {"31738372": "(No title fetched)", "34146512": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment."}, "topk_used": ["34146512", "29507718", "15783264", "37943150", "20413854", "17182990", "29441009", "21971452", "31738372", "19585948", "31574510", "19278690", "21705182", "24983746", "22546352", "21905097", "36281662", "25203109", "16974109", "21996556"], "topk_titles": {"34146512": "(No title fetched)", "29507718": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "20413854": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "31738372": "(No title fetched)", "19585948": "Novel strategies for the prevention of dementia from Alzheimer's disease.", "31574510": "(No title fetched)", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "24983746": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "36281662": "(No title fetched)", "25203109": "(No title fetched)", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly."}, "gold_ideal": ["No. Pioglitazone did not delay the onset of mild cognitive impairment."], "gold_exact": ["no"]}
{"id": "65ce88b71930410b13000001", "question": "Is Lecanemab approved for Alzheimer\u2019s Disease?", "answer": "Yes, Lecanemab has been recently approved by the FDA for the treatment of Alzheimer's disease [36931947] The [36931947] states that Lecanemab has been approved for this indication [37479527] The second [37682322], which discusses the pioneering nature of Lecanemab, supports this claim [37682322]", "pmids": ["36931947", "37479527", "37682322"], "pmid_titles": {"36931947": "(No title fetched)", "37479527": "Lecanemab: Looking Before We Leap.", "37682322": "(No title fetched)"}, "topk_used": ["37357276", "37927263", "37902139", "37682322", "37414156", "37060386", "37831471", "37676096", "36931947", "38021811", "38095822", "37955845", "37490245", "37334596", "36856953", "37479527", "37045461", "23334070", "37389302", "37639602"], "topk_titles": {"37357276": "(No title fetched)", "37927263": "(No title fetched)", "37902139": "(No title fetched)", "37682322": "(No title fetched)", "37414156": "(No title fetched)", "37060386": "(No title fetched)", "37831471": "(No title fetched)", "37676096": "(No title fetched)", "36931947": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "37490245": "(No title fetched)", "37334596": "(No title fetched)", "36856953": "(No title fetched)", "37479527": "Lecanemab: Looking Before We Leap.", "37045461": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37389302": "(No title fetched)", "37639602": "(No title fetched)"}, "gold_ideal": ["Yes. Lecanemab (Leqembi\u00ae) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment due to AD or mild AD dementia) with confirmed brain amyloid pathology."], "gold_exact": ["yes"]}
{"id": "6616a122fdcbea915f000058", "question": "Has statin use been associated with a higher risk of dementia?", "answer": "Question: Has statin use been associated with a higher risk of dementia? [24681022] : [12345678] Higher potency and longer cumulative duration of statin use were required for reducing the risk of incident dementia in male patients than in female patients [30337635] [24681022] Higher potency and longer cumulative duration of statin use were required for reducing the risk of incident dementia in male patients than in female patients [30087076]", "pmids": ["24681022", "30337635", "30087076"], "pmid_titles": {"24681022": "(No title fetched)", "30337635": "(No title fetched)", "30087076": "(No title fetched)"}, "topk_used": ["24681022", "30087076", "30337635", "29507718", "16009757", "12084801", "24578458", "31574510", "35305172", "22269162", "37291702", "26080283", "32583471", "23461525", "29247073", "30045255", "24075740", "22451317", "20413854", "34871380"], "topk_titles": {"24681022": "(No title fetched)", "30087076": "(No title fetched)", "30337635": "(No title fetched)", "29507718": "(No title fetched)", "16009757": "(No title fetched)", "12084801": "(No title fetched)", "24578458": "(No title fetched)", "31574510": "(No title fetched)", "35305172": "(No title fetched)", "22269162": "(No title fetched)", "37291702": "(No title fetched)", "26080283": "(No title fetched)", "32583471": "(No title fetched)", "23461525": "(No title fetched)", "29247073": "(No title fetched)", "30045255": "(No title fetched)", "24075740": "(No title fetched)", "22451317": "(No title fetched)", "20413854": "(No title fetched)", "34871380": "(No title fetched)"}, "gold_ideal": ["According to a systematic review and meta-analysis of observational studies, statin use is not associated with a higher risk of dementia or Alzheimer's disease. In fact, the study found that statin use was associated with a decreased risk of both dementia and Alzheimer's disease. This reduction in risk was similar for both lipophilic and hydrophilic statins, but high-potency statins showed a greater efficacy in reducing dementia risk compared to low-potency statins. These findings suggest that statin treatment does not carry a neurocognitive risk and may even have a potential favorable role in reducing the risk of dementia. However, randomized clinical trials are needed to further explore this potential neuroprotective effect.", "No, there is no strong evidence to suggest that statin use is associated with a higher risk of dementia. In fact, some studies have found that statin use may be linked to a reduced risk of dementia, particularly among patients with stroke. However, it's important to note that the relationship between statins and dementia risk is complex and may depend on various factors such as the type and duration of statin use, age, sex, and other health conditions. Further research is needed to fully understand the potential benefits and risks of statin use in relation to dementia."], "gold_exact": ["yes"]}
{"id": "663014c8187cba990d000020", "question": "What is Alzheimer's disease?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] This neurodegenerative disorder is the most common cause of progressive dementia in the elderly [29441009] Based on the evidence provided, Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [23861639]", "pmids": ["37488880", "29441009", "23861639"], "pmid_titles": {"37488880": "(No title fetched)", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["37943150", "37488880", "36281662", "29441009", "38075821", "38021811", "24434253", "22009441", "27358062", "35558050", "24132372", "29298722", "37264659", "37556728", "23861639", "20826658", "21715616", "29574591", "28435465", "32183348"], "topk_titles": {"37943150": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "38075821": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "22009441": "(No title fetched)", "27358062": "(No title fetched)", "35558050": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "37264659": "(No title fetched)", "37556728": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "29574591": "(No title fetched)", "28435465": "(No title fetched)", "32183348": "(No title fetched)"}, "gold_ideal": ["Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease.", "Alzheimer's disease is a neurodegenerative disorder characterized by amyloid beta plaque and neurofibrillary tangles.", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain.", "Alzheimer's disease is a neurodegenerative disorder. It's characterized by the accumulation of amyloid beta plaque and neurofibrillary tangles in the brain, leading to memory loss and cognitive decline", "Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of amyloid in the brain, leading to memory loss and cognitive decline"], "gold_exact": []}
{"id": "66097092fdcbea915f000010", "question": "Amyloid-\u03b2 is associated with what diseases?", "answer": "Amyloid-\u03b2 is associated with Alzheimer's disease and cerebral amyloid angiopathy, as well as with other biomarkers indicative of early Alzheimer's disease in normal older people [26614753] These highly ordered protein aggregates have been, for a long time, mainly associated with human neurodegenerative diseases such as Alzheimer's disease [32093040]", "pmids": ["26614753", "32093040"], "pmid_titles": {"26614753": "(No title fetched)", "32093040": "(No title fetched)"}, "topk_used": ["25783987", "33513738", "26614753", "38075821", "37556728", "37905874", "36302506", "35892582", "36281662", "32341983", "32093040", "22957288", "37652560", "36687366", "37943150", "37264659", "29574591", "14572915", "35558050", "37489069"], "topk_titles": {"25783987": "(No title fetched)", "33513738": "(No title fetched)", "26614753": "(No title fetched)", "38075821": "(No title fetched)", "37556728": "(No title fetched)", "37905874": "(No title fetched)", "36302506": "(No title fetched)", "35892582": "(No title fetched)", "36281662": "(No title fetched)", "32341983": "(No title fetched)", "32093040": "(No title fetched)", "22957288": "Amyloid \u03b2-Related Angiitis Causing Coma Responsive to Immunosuppression.", "37652560": "(No title fetched)", "36687366": "(No title fetched)", "37943150": "(No title fetched)", "37264659": "(No title fetched)", "29574591": "(No title fetched)", "14572915": "(No title fetched)", "35558050": "(No title fetched)", "37489069": "(No title fetched)"}, "gold_ideal": ["Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and others.", "Amyloid-\u00ce\u00b2 (A\u00ce\u00b2) is associated with Alzheimer's disease (AD) and is known to promote chronic inflammatory responses in the brain. Additionally, A\u00ce\u00b2 accumulation is also found in age-related macular degeneration (AMD) and glaucoma.", "Amyloid-\u03b2 has been implicated in several neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), and progressive supranuclear palsy. Additionally, research has shown that amyloid-\u03b2 may play a role in other neurological conditions such as Parkinson's disease and amyotrophic lateral sclerosis, as well as in non-neurological disorders like cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta is associated with a range of diseases, primarily neurodegenerative and retinal disorders. It is most notably linked to Alzheimer's disease but also connected to other conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 has been associated with neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, it has been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 (A\u03b2) is a peptide with 38-42 amino acids associated with the pathogenesis of Alzheimer's disease (AD). The most common form, A\u03b242, is the most neurotoxic.", "Amyloid-\u03b2 is associated with several neurodegenerative diseases including Alzheimer's disease (AD), Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP) and progressive supranuclear palsy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and other amyloid diseases.", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, Alzheimer's disease, Parkinson's disease, cancer, traumatic brain injury, Glaucoma, and age-related macular degeneration.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, and amyotrophic lateral scler", "Amyloid-beta is associated with several diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 (A\u03b2) is associated with several diseases beyond Alzheimer's disease, including Lewy body disease (LBD), multiple system atrophy (MSA), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), and progressive supranuclear palsy (PSP). A\u03b2 deposition has also been linked to other neurological diseases, such as Parkinson's disease, amyotrophic lateral sclerosis, and retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has been implicated in cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease, amyloid-\u03b2-induced neurotoxicity and neurodegeneration, and other diseases.", "Amyloid-\u03b2 is associated with Alzheimer's disease, multiple sclerosis, and other neurodegenerative diseases.", "Amyloid-\u03b2 is associated with neurodegenerative diseases beyond Alzheimer's disease, including Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.", "Amyloid-\u00ce\u00b2 is associated with Alzheimer's disease and age-related macular degeneration.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes, among others.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy.", "Amyloid-\u03b2 is associated with Alzheimer's Disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cardiovascular disease, cancer, traumatic brain injury, age-related macular degeneration, and glaucoma.", "Amyloid-\u03b2 is associated with Alzheimer's disease, cerebral amyloid angiopathy, and AD.", "Amyloid-\u03b2 is associated with neurodegenerative diseases such as Alzheimer's disease, Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration-TDP-43, and progressive supranuclear palsy. It has also been implicated in other conditions including Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-beta (A\u03b2) is associated with various neurodegenerative diseases, including Alzheimer's disease (AD), Lewy body disease (LBD), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP), Parkinson's disease, amyotrophic lateral sclerosis, glaucoma, and age-related macular degeneration. A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 (A\u03b2) has been associated with several neurological diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration. Additionally, A\u03b2 has also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes.", "Amyloid-\u03b2 is associated with Alzheimer's disease as well as many other neurodegenerative diseases like Lewy body disease, multiple system atrophy, frontotemporal lobar degeneration, Parkinson's disease, and amyotrophic lateral sclerosis, as well as retinal neurodegenerative diseases like Glaucoma and age-related macular degeneration and progressive supranuclear palsy These proteins have also been linked to cardiovascular disease, cancer, traumatic brain injury, and diabetes", "Amyloid-\u03b2 is associated with amyotrophic lateral sclerosis, cardiovascular disease, multiple system atrophy, progressive supranuclear palsy, cancer, traumatic brain injury.", "Amyloid-\u03b2 is primarily associated with Alzheimer's disease and cerebral amyloid angiopathy.", "Amyloid-\u03b2 is associated with Alzheimer's disease and cerebral amyloid angiopathy.", "\nAmyloid-\u03b2 is associated with Alzheimer's disease, Down syndrome, Parkinson's disease, and certain types of cancer. (Note: The role of amyloid-\u03b2 in Parkinson's disease and cancer is less clear.)", "Amyloid is associated with various diseases such as Alzheimer's disease, Parkinson's disease, type II diabetes, prion diseases, neurodevelopmental and neurodegenerative disorders, metabolic disorders, and certain types of cancer.", "Amyloid-\u03b2 is associated with a range of diseases including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, Glaucoma, age-related macular degeneration, cardiovascular disease, cancer, traumatic brain injury, and diabetes."], "gold_exact": [["Alzheimer's disease"], ["Lewy Body diseasse"], ["frontotemporal lobar degeneration"], ["Progressive Supranuclear palsy"], ["Cardiovascular disease"], ["Traumatic brain injury"], ["Diabetes"], ["Parkinson's disease"], ["age-related macular degeneration"], ["Glaucoma"], ["amyotrophic lateral sclerosis,"]]}
{"id": "65cfa6201930410b1300000e", "question": "Is Patisiran used for Transthyretin Cardiac Amyloidosis?", "answer": "Question: Is Patisiran used for Transthyretin Cardiac Amyloidosis? [37888916] : 1 [37490245] Yes, Patisiran is a disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted [33841597]", "pmids": ["37888916", "37490245", "33841597"], "pmid_titles": {"37888916": "(No title fetched)", "37490245": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37456349", "37888916", "33841597", "37599395", "36336119", "28893208", "37288260", "28646538", "28922609", "19363993", "34315986", "29247073", "33023198", "37905874", "21624562", "28920433", "37639602", "22815077", "26243339", "37490245"], "topk_titles": {"37456349": "(No title fetched)", "37888916": "(No title fetched)", "33841597": "(No title fetched)", "37599395": "(No title fetched)", "36336119": "(No title fetched)", "28893208": "(No title fetched)", "37288260": "(No title fetched)", "28646538": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "34315986": "(No title fetched)", "29247073": "(No title fetched)", "33023198": "(No title fetched)", "37905874": "(No title fetched)", "21624562": "(No title fetched)", "28920433": "(No title fetched)", "37639602": "(No title fetched)", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "26243339": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["Yes. Patisiran can be used for Transthyretin Cardiac Amyloidosis"], "gold_exact": ["yes"]}
{"id": "660d7324fdcbea915f000040", "question": "How many people affected by Parkinson's Disease develop dementia?", "answer": "The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [21624562] The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [17182990] The diagnosis of dementia, along with the prediction of who will develop dementia, has been assisted by magnetic resonance imaging and positron emission tomography (PET) by using [(18)F]fluorodeoxyglucose (FDG) [20929585]", "pmids": ["21624562", "17182990", "20929585"], "pmid_titles": {"21624562": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy."}, "topk_used": ["8237620", "23567438", "21971452", "21624562", "17244848", "35558050", "17182990", "19278690", "17303592", "21996556", "28272510", "21783505", "23597030", "29441009", "20929585", "14699432", "18816693", "22009441", "1406817", "24075740"], "topk_titles": {"8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "23567438": "(No title fetched)", "21971452": "(No title fetched)", "21624562": "(No title fetched)", "17244848": "Chronic distress, age-related neuropathology, and late-life dementia.", "35558050": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "19278690": "(No title fetched)", "17303592": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "28272510": "(No title fetched)", "21783505": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "29441009": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "18816693": "(No title fetched)", "22009441": "(No title fetched)", "1406817": "A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.", "24075740": "(No title fetched)"}, "gold_ideal": ["About 26.3% of individuals with Parkinson's Disease develop Parkinson's Disease Dementia (PDD), indicating a significant concern for those affected. However, this number may underestimate cognitive decline cases as not all are classified as PDD; other forms such as Lewy body dementia or Alzheimer's disease can also occur in these patients.", "Approximately a quarter of people affected by Parkinson's disease develop Parkinsonn's disease dementia."], "gold_exact": ["25%"]}
{"id": "550324d7e9bde6963400002f", "question": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?", "answer": "One study found an association between the TREM2 gene polymorphism rs75932628-T and the lowest dementia risk among socially isolated individuals (23391427) [19153372] Another study reported an association between the same polymorphism and the highest dementia risk among individuals with low neuroticism (23391427) [25274849] However, even low neuroticism alone was associated with the lowest dementia risk (23391427) [23567438]", "pmids": ["19153372", "25274849", "23567438"], "pmid_titles": {"19153372": "Personality and lifestyle in relation to dementia incidence.", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "23567438": "(No title fetched)"}, "topk_used": ["15783264", "18694539", "16314587", "23040035", "25274849", "16974109", "20973606", "23079898", "9924832", "10718200", "21905097", "21427641", "23391427", "23567438", "29441009", "19278690", "12767492", "19153372", "37943150", "23150934"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "18694539": "(No title fetched)", "16314587": "Neuroticism, extraversion, and mortality in a defined population of older persons.", "23040035": "(No title fetched)", "25274849": "Midlife personality and risk of Alzheimer disease and distress: a 38-year follow-up.", "16974109": "Chronic psychological distress and risk of Alzheimer's disease in old age.", "20973606": "(No title fetched)", "23079898": "(No title fetched)", "9924832": "Premorbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms?", "10718200": "(No title fetched)", "21905097": "Personality changes in Alzheimer's disease: a systematic review.", "21427641": "(No title fetched)", "23391427": "(No title fetched)", "23567438": "(No title fetched)", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "19153372": "Personality and lifestyle in relation to dementia incidence.", "37943150": "(No title fetched)", "23150934": "(No title fetched)"}, "gold_ideal": ["High neuroticism is associated with increased risk to develop Alzheimer's disease. Greater neuroticism is also associated more advanced Alzheimer's disease neuropathology and younger age of dementia onset. Neuroticism's association with late-life dementia mainly reflects vulnerability to stress and anxiety. Neuroticism moderates the relationship between APOE-4 genotype and cognitive outcomes in elderly. Neuroticism also predicts Mild Cognitive Impairment, Aging-Associated Cognitive Decline and cognitive decline among elderly. Alzheimer's disease patients have greater neuroticism relative to controls."], "gold_exact": []}
{"id": "51588c34d24251bc05000095", "question": "Is TREM2 associated with Alzheimer's disease in humans?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to identify potential mechanisms underlying the association [20942790]", "pmids": ["23391427", "23150908", "20942790"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "23692967", "23407992", "24041969", "23533697", "24119542", "24002183", "17088018", "23582655", "23510020", "15783264", "19278690", "37264659", "29298722", "34315986", "20942790"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "23692967": "(No title fetched)", "23407992": "(No title fetched)", "24041969": "(No title fetched)", "23533697": "(No title fetched)", "24119542": "(No title fetched)", "24002183": "(No title fetched)", "17088018": "(No title fetched)", "23582655": "(No title fetched)", "23510020": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "37264659": "(No title fetched)", "29298722": "(No title fetched)", "34315986": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease."}, "gold_ideal": ["TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530cefaaad0bf1360c000004", "question": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?", "answer": "Yes, bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease [20497044] Based on the provided evidence, this suggests that bapineuzumab may be an effective treatment option for this condition [22305802]", "pmids": ["20497044", "22305802"], "pmid_titles": {"20497044": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis."}, "topk_used": ["23599675", "20497044", "23416764", "20154508", "23085451", "23334070", "22473769", "23931438", "26815584", "20505438", "23582316", "23809364", "23847530", "23334069", "21091109", "28649604", "22305802", "20189881", "21501112", "23574434"], "topk_titles": {"23599675": "Bapineuzumab, an investigational agent for Alzheimer's disease.", "20497044": "(No title fetched)", "23416764": "Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23085451": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22473769": "Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.", "23931438": "(No title fetched)", "26815584": "(No title fetched)", "20505438": "A single ascending dose study of bapineuzumab in patients with Alzheimer disease.", "23582316": "(No title fetched)", "23809364": "Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21091109": "(No title fetched)", "28649604": "(No title fetched)", "22305802": "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.", "20189881": "11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.", "21501112": "(No title fetched)", "23574434": "(No title fetched)"}, "gold_ideal": ["Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."], "gold_exact": ["no"]}
{"id": "531a31a1b166e2b806000035", "question": "Is TREM2 associated with Alzheimer's disease?", "answer": "Yes, TREM2 is associated with the risk of Alzheimer's disease in Spanish population based on two recent studies reporting the association of rs75932628-T in the TREM2 gene with the risk for AD [23391427] The studies suggest that this variant may contribute to the development of AD by altering the expression of TREM2 and its downstream signaling pathways [23150908] However, additional studies are needed to confirm these findings and to elucidate the underlying mechanisms [18620875]", "pmids": ["23391427", "23150908", "18620875"], "pmid_titles": {"23391427": "(No title fetched)", "23150908": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["23391427", "23150934", "23150908", "23380991", "23462268", "24041969", "23407992", "23692967", "18620875", "37264659", "24119542", "23533697", "23582655", "17088018", "29298722", "24002183", "34315986", "19958468", "20154508", "37556728"], "topk_titles": {"23391427": "(No title fetched)", "23150934": "(No title fetched)", "23150908": "(No title fetched)", "23380991": "(No title fetched)", "23462268": "(No title fetched)", "24041969": "(No title fetched)", "23407992": "(No title fetched)", "23692967": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "37264659": "(No title fetched)", "24119542": "(No title fetched)", "23533697": "(No title fetched)", "23582655": "(No title fetched)", "17088018": "(No title fetched)", "29298722": "(No title fetched)", "24002183": "(No title fetched)", "34315986": "(No title fetched)", "19958468": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37556728": "(No title fetched)"}, "gold_ideal": ["A rare variant of the TREM2 gene, which encodes the triggering receptor encoded in myeloid cells 2 (rs75932628-T) causing a R47H substitution has been associated with both early and late onset Alzheimer's disease in various populations.  Emerging evidence has demonstrated that TREM2 could suppress inflammatory response by repression of microglia-mediated cytokine production and secretion, which may prevent inflammation-induced bystander damage of neurons. Higher levels of TREM2 mRNA (p = 0.002) and protein (p < 0.001) were identified in AD patients which indicates that TREM2 might serve as a novel noninvasive biomarker for AD diagnosis. Based on the potential protective actions of TREM2 in AD pathogenesis, targeting TREM2 might provide new opportunities for AD treatment."], "gold_exact": ["yes"]}
{"id": "5311bf53e3eabad021000006", "question": "Which are the biotracers used for detection of Alzheimer's disease using PET?", "answer": "Alzheimer's disease is a neurodegenerative disorder characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [37488880] Platelet biomarkers such as soluble fms-like tyrosine kinase 1 (sFlt-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and soluble intercellular adhesion molecule-1 (sICAM-1) have been shown to be associated with Alzheimer's disease in various studies [24175175] However, the specificity and sensitivity of these biomarkers for early Alzheimer's disease detection are lower than those provided by high-affinity ligands for \u03b2-amyloid (A\u03b2) [23527322]", "pmids": ["37488880", "24175175", "23527322"], "pmid_titles": {"37488880": "(No title fetched)", "24175175": "(No title fetched)", "23527322": "(No title fetched)"}, "topk_used": ["23966257", "16712496", "24194552", "19164222", "20580647", "37943150", "23527322", "17182990", "20538373", "21683932", "19278690", "29441009", "21624562", "37488880", "22529838", "23420460", "24175175", "36281662", "22009441", "22982358"], "topk_titles": {"23966257": "Amyloid imaging: the court of public opinion.", "16712496": "The role of MRI and PET/SPECT in Alzheimer's disease.", "24194552": "(No title fetched)", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "20580647": "Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease.", "37943150": "(No title fetched)", "23527322": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "20538373": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease.", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "21624562": "(No title fetched)", "37488880": "(No title fetched)", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "24175175": "(No title fetched)", "36281662": "(No title fetched)", "22009441": "(No title fetched)", "22982358": "(No title fetched)"}, "gold_ideal": ["Pittsburgh compound B (PIB) was the first radiotracer capable of highlighting deposits of beta-amyloid\u2014one pathological hallmark of Alzheimer's disease\u2014in living individuals during a PET scan. The Alzheimer's Association helped fund early PIB development. The Association in 2006 also awarded a $2.1 million grant to the Alzheimer's Disease Neuroimaging Initiative (ADNI) to expand this long-term, nationwide study to include PIB-PET imaging.\n\n18F flutemetamol (flute), another radiotracer that highlights beta-amyloid in a PET scan, is structurally identical to PIB except for one fluorine atom in place of a carbon atom. That small chemical change enables flutemetamol to remain stable significantly longer than does PIB, potentially increasing its usefulness outside research settings. In phase II study results reported in the Annals of Neurology, flutemetamol performed similarly to PIB. Additional testing is under way.\n\nFlorbetapir F 18 (18F-AV-45) is also a radiotracer that highlights brain beta-amyloid during a PET scan. At the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD), florbetapir's developer first reported data, later published in the JAMA, showing nearly perfect correlation between brain amyloid levels detected by florbetapir PET scans in study volunteers and levels found in autopsies of the same individuals a few months later. The developer has sought Food and Drug Administration (FDA) approval to market florbetapir under the brand name Amyvid. The FDA has said it will withhold approval until the developer establishes a professional training program to ensure accuracy and consistency in reading and interpreting Amyvid scans.\n\nFlorbetaben (BAY 94-9172) is another radiotracer designed to detect beta-amyloid during a PET scan. Phase II study results and other florbetaben data were reported at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease (AAICAD). Phase II data were also later published in Lancet Neurology. Further studies are now under way."], "gold_exact": [["Pittsburgh compound B"], ["Florbetaben (BAY 94-9172)"], ["Florbetapir F 18 (18F-AV-45)"], ["18F flutemetamol (flute)"]]}
{"id": "5311d130e3eabad021000009", "question": "Which proteins in the cerebro-spinal fluid can be used for early diagnosis of Alzheimer's disease?", "answer": "Alzheimer's disease (AD) may be facilitated by cerebro-spinal fluid (CSF) biomarkers in combination with imaging and clinical assessments, as determined by the presence of ApoE genotype and tau protein level in CSF [19278690] However, these markers are poorly sensitive to the progressive disease stages, as demonstrated by the absence of significant differences in CSF biomarkers between early and late stages of AD [19228370]", "pmids": ["19278690", "19228370"], "pmid_titles": {"19278690": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics."}, "topk_used": ["11204323", "8180825", "14699432", "20875798", "21971452", "19363993", "24133408", "19324376", "21996556", "23847530", "29182052", "20558869", "10510805", "19278690", "37556728", "37943150", "15975056", "19228370", "29441009", "23527322"], "topk_titles": {"11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "14699432": "Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.", "20875798": "(No title fetched)", "21971452": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "24133408": "Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29182052": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "10510805": "[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome].", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "37943150": "(No title fetched)", "15975056": "Neurodegenerative disorders and cholesterol.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "29441009": "(No title fetched)", "23527322": "(No title fetched)"}, "gold_ideal": ["CSF is a clear fluid that bathes and cushions the brain and spinal cord. Adults have about 1 pint of CSF, which physicians can sample through a minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests that Alzheimer's disease in its earliest stages may cause changes in CSF levels of tau and beta-amyloid, two proteins that form abnormal brain deposits strongly linked to the disease."], "gold_exact": [["phosphorylated tau"], ["beta-amyloid"]]}
{"id": "5162e44f298dcd4e5100004a", "question": "The protein neprilysin  has an positive effect on Alzheimer disease, how can it be delivered to the brain?", "answer": "The protein neprilysin has an positive effect on Alzheimer disease, as it has been shown to be delivered to the brain through intra-peritoneal injection in a mouse model of AD [21304989] This delivery method has been tested in previous studies and has shown promising results [8180825] However, further research is needed to fully understand the mechanism of action and optimize delivery methods for neprilysin gene therapy in humans [20817034]", "pmids": ["21304989", "8180825", "20817034"], "pmid_titles": {"21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20817034": "(No title fetched)"}, "topk_used": ["23503602", "23378928", "21304989", "17760499", "19469700", "22751177", "15783264", "20817034", "29441009", "37488880", "37943150", "36281662", "19278690", "21996556", "37556728", "17883890", "19228370", "8180825", "32093040", "21705182"], "topk_titles": {"23503602": "Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice.", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.", "21304989": "Peripheral delivery of a CNS targeted, metalo-protease reduces a\u03b2 toxicity in a mouse model of Alzheimer's disease.", "17760499": "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.", "19469700": "Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells.", "22751177": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "20817034": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "37943150": "(No title fetched)", "36281662": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37556728": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "32093040": "(No title fetched)", "21705182": "(No title fetched)"}, "gold_ideal": ["The protein neprilysin can be deliverered to the brain (crossing the blood brain barrier) through: gene tranfer, transgenesis, gene induction, ex-vivo gene therapy, intracardiac (peripheral) administration of viral neprilysin construct, syringe-focused ultrasound device, convection-enhanced delivery and the use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"], "gold_exact": [["Gene transfer with viral vectors"], ["Gene transfer with non-viral vectors"], ["Transgenesis"], ["Gene Induction"], ["Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein"], ["ex vivo gene therapy"], ["Intracardiac (peripheral) administration of viral neprilysin construct"], ["Syringe-focused ultrasound device"], ["Convection-enhanced delivery"], ["Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes"]]}
{"id": "52fc94db2059c6d71c000074", "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.", "answer": "Anti-amyloid-beta monoclonal antibodies have been investigated in clinical trials for the treatment of Alzheimer disease [38095822] Lecanemab, an anti-amyloid beta monoclonal antibody, has shown statistically significant cognitive benefits in phase III trials [20375655] Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease [24255592]", "pmids": ["38095822", "20375655", "24255592"], "pmid_titles": {"38095822": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease."}, "topk_used": ["37060386", "24255592", "37831471", "37414156", "23334070", "20154508", "38095822", "37955845", "20375655", "28649604", "37902139", "23847530", "23334069", "21987394", "22134132", "19923550", "24760112", "38021811", "37389302", "21683932"], "topk_titles": {"37060386": "(No title fetched)", "24255592": "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "38095822": "(No title fetched)", "37955845": "(No title fetched)", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "28649604": "(No title fetched)", "37902139": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.", "22134132": "Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.", "19923550": "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.", "24760112": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37389302": "(No title fetched)", "21683932": "Clinical amyloid imaging in Alzheimer's disease."}, "gold_ideal": ["Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.", "Bapineuzumab\nSolanezumab\nPonezumab\nGantenerumab"], "gold_exact": [["Bapineuzumab", "bapineuzumab"], ["Solanezumab", "solanezumab"], ["Ponezumab", "ponezumab"], ["Gantenerumab"]]}
{"id": "533ada5efd9a95ea0d000001", "question": "Is there any evidence of dysregulated long non coding RNAs and Alzheimer's disease?", "answer": "Experimental evidence suggests that dysregulated long non-coding RNAs and Alzheimer's disease are associated with each other [19936094] Specifically, various coding genes representing multiple functional categories are downregulated in blood mononuclear cells (BMC) of patients with sporadic Alzheimer disease (AD), while predicted target genes downregulated in Alzheimer BMC that correlated with the upregulated miRNAs were largely represented in the func [21996556] However, additional experimental evidence is needed to confirm these findings [23624169]", "pmids": ["19936094", "21996556", "23624169"], "pmid_titles": {"19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "23624169": "(No title fetched)"}, "topk_used": ["19881909", "29441009", "37943150", "22081608", "20888417", "19278690", "15783264", "35558050", "36281662", "21971452", "19936094", "23624169", "21996556", "37488880", "22009441", "22203915", "27358062", "37264659", "8180825", "20826658"], "topk_titles": {"19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "29441009": "(No title fetched)", "37943150": "(No title fetched)", "22081608": "(No title fetched)", "20888417": "(No title fetched)", "19278690": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "35558050": "(No title fetched)", "36281662": "(No title fetched)", "21971452": "(No title fetched)", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "23624169": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37488880": "(No title fetched)", "22009441": "(No title fetched)", "22203915": "(No title fetched)", "27358062": "(No title fetched)", "37264659": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines."}, "gold_ideal": ["It is becoming increasingly evident that long non coding RNAs (lncRNAs) play a role on neurodegenerative diseases such as Alzheimer (AD).  BACE1-AS, GDNFOS and 17A are examples of these lncRNAs. In some instances those lncRNAs are embedded or transcribed from the opposite strand of coding genes."], "gold_exact": []}
{"id": "532bf6f2d6d3ac6a34000015", "question": "Is there any research that relates the function of Notch Signaling with Alzheimer Disease?", "answer": "Yes, there is evidence that suggests that gamma-Secretase is critically involved in the Notch pathway and in Alzheimer's disease [19958468] Specifically, drugs that regulate the production of Abeta by inhibiting or modulating gamma-secretase activity have been shown to provide a disease-modifying effect on Alzheimer's disease, although recent studies suggest that gamma-secretase plays important roles in cellular signaling including Notch [18038124]", "pmids": ["19958468", "18038124"], "pmid_titles": {"19958468": "(No title fetched)", "18038124": "(No title fetched)"}, "topk_used": ["24099003", "15783264", "21971452", "22122056", "19278690", "19958468", "18038124", "23570941", "22792182", "24983746", "37943150", "29441009", "23624169", "35558050", "37488880", "20942790", "21768095", "23197721", "36281662", "15766275"], "topk_titles": {"24099003": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "21971452": "(No title fetched)", "22122056": "(No title fetched)", "19278690": "(No title fetched)", "19958468": "(No title fetched)", "18038124": "(No title fetched)", "23570941": "(No title fetched)", "22792182": "(No title fetched)", "24983746": "(No title fetched)", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "23624169": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "21768095": "(No title fetched)", "23197721": "Alzheimer's disease: presenilin 2-sparing \u03b3-secretase inhibition is a tolerable A\u03b2 peptide-lowering strategy.", "36281662": "(No title fetched)", "15766275": "(No title fetched)"}, "gold_ideal": ["Notch signaling is an evolutionarily conserved pathway, which is fundamental for neuronal development and specification. In the last decade, increasing evidence has pointed out an important role of this pathway beyond embryonic development, indicating that Notch also displays a critical function in the mature brain of vertebrates and invertebrates. This pathway appears to be involved in neural progenitor regulation, neuronal connectivity, synaptic plasticity and learning/memory. In addition, Notch appears to be aberrantly regulated in neurodegenerative diseases, including Alzheimer's disease and ischemic injury"], "gold_exact": ["yes"]}
{"id": "5156beb4d24251bc05000089", "question": "Can Alzheimer's disease related miRNAs be detected in patients' blood?", "answer": "Yes, Alzheimer's disease related miRNAs can be detected in patients' blood using the provided evidence [22155483] Specifically, microRNAs (miRNAs) such as miR-298, which regulates \u03b2-amyloid (A\u03b2) precursor protein-converting enzyme-1 (BACE1), have been shown to be downregulated in BMC of patients with sporadic Alzheimer disease (AD) [23030236] This suggests that miR-298 may play a role in the pathogenesis of AD and could potentially serve as a target for therapeutic intervention [23293020]", "pmids": ["22155483", "23030236", "23293020"], "pmid_titles": {"22155483": "(No title fetched)", "23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples."}, "topk_used": ["23030236", "23293020", "19881909", "19936094", "21548758", "37943150", "23624169", "29441009", "24754513", "24633805", "26258756", "23054683", "21709374", "22155483", "22472873", "22009441", "19324376", "37488880", "23065742", "21971452"], "topk_titles": {"23030236": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "19936094": "MicroRNA expression in Alzheimer blood mononuclear cells.", "21548758": "(No title fetched)", "37943150": "(No title fetched)", "23624169": "(No title fetched)", "29441009": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "24633805": "(No title fetched)", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23054683": "(No title fetched)", "21709374": "Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: genetics and expression analysis.", "22155483": "(No title fetched)", "22472873": "(No title fetched)", "22009441": "(No title fetched)", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "37488880": "(No title fetched)", "23065742": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["Yes. It has been demonstrated that blood miRNAs could be useful as biomarkers in Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "530b4f49970c65fa6b00000a", "question": "Can we use platelet biomarkers to study Alzheimer's disease?", "answer": "Yes, the negative efficacy study examining the \u03b3-secretase inhibitor semagacestat in mild to moderate Alzheimer's disease (AD) included a number of biomarkers of the disease as well as safety outcomes [26064192] Specifically, the study included the following biomarkers: 1 [23293020] Platelet biomarkers (e.g., C-reactive protein, fibrinogen, and von Willebrand factor) 2 [24175175]", "pmids": ["26064192", "23293020", "24175175"], "pmid_titles": {"26064192": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "24175175": "(No title fetched)"}, "topk_used": ["24175175", "19278690", "22579745", "21971452", "23293020", "21624562", "29182052", "24194552", "31794792", "37943150", "17182990", "26064192", "20538373", "20875798", "29441009", "35558050", "20929585", "8180825", "19324376", "23030236"], "topk_titles": {"24175175": "(No title fetched)", "19278690": "(No title fetched)", "22579745": "(No title fetched)", "21971452": "(No title fetched)", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "21624562": "(No title fetched)", "29182052": "(No title fetched)", "24194552": "(No title fetched)", "31794792": "(No title fetched)", "37943150": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "26064192": "(No title fetched)", "20538373": "(No title fetched)", "20875798": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23030236": "(No title fetched)"}, "gold_ideal": ["Yes, platelet biomarkers can be used to study Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "56c1f033ef6e39474100004f", "question": "Describe clinical presentation of Parkinsonism with dementia of Guadeloupe syndrome.", "answer": "Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic hypotheses Abstract Atypical parkinsonism on Guadeloupe, com [21783505]", "pmids": ["21783505"], "pmid_titles": {"21783505": "(No title fetched)"}, "topk_used": ["17303592", "16092100", "11912113", "18816693", "21783505", "18941145", "12217621", "15783264", "17702273", "21971452", "22009441", "21903360", "9050085", "23040035", "30045255", "20678581", "23567438", "19278690", "37556728", "21149978"], "topk_titles": {"17303592": "(No title fetched)", "16092100": "(No title fetched)", "11912113": "(No title fetched)", "18816693": "(No title fetched)", "21783505": "(No title fetched)", "18941145": "(No title fetched)", "12217621": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "17702273": "(No title fetched)", "21971452": "(No title fetched)", "22009441": "(No title fetched)", "21903360": "(No title fetched)", "9050085": "(No title fetched)", "23040035": "(No title fetched)", "30045255": "(No title fetched)", "20678581": "(No title fetched)", "23567438": "(No title fetched)", "19278690": "(No title fetched)", "37556728": "(No title fetched)", "21149978": "(No title fetched)"}, "gold_ideal": ["Parkinsonism with dementia of Guadeloupe is a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Based on the presence or the absence of supranuclear gaze palsy, two subgroups of patients can be distinguished."], "gold_exact": []}
{"id": "56bce51cd36b5da37800000a", "question": "What is the role of neurogranin in Alzheimer's disease patients?", "answer": "The role of neurogranin in Alzheimer's disease patients is unclear based on the evidence provided [37488880] However, it has been shown to play a role in cancer progression, as evidenced by the presence of gamma-secretase complex in tumors [19299585]", "pmids": ["37488880", "19299585"], "pmid_titles": {"37488880": "(No title fetched)", "19299585": "(No title fetched)"}, "topk_used": ["20875798", "15783264", "26136856", "23597030", "37943150", "33023198", "37488880", "29441009", "35558050", "10214944", "29298722", "20678074", "8180825", "38021811", "19278690", "23316412", "19299585", "36281662", "21487536", "22009441"], "topk_titles": {"20875798": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "26136856": "(No title fetched)", "23597030": "Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.", "37943150": "(No title fetched)", "33023198": "(No title fetched)", "37488880": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "10214944": "(No title fetched)", "29298722": "(No title fetched)", "20678074": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "19299585": "(No title fetched)", "36281662": "(No title fetched)", "21487536": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Dendritic protein neurogranin is markedly increased in cerebrospinal fluid in Alzheimer's disease patients.  Neurogranin might reflect the neurodegenerative processes within the brain, indicating a role for neurogranin as a potential novel clinical biomarker for synaptic degeneration in AD.\nNeurogranin is important for synaptic plasticity and memory."], "gold_exact": []}
{"id": "58a2fac960087bc10a000009", "question": "Which are the side effects during tacrine administration in patients with Alzheimer's Disease?", "answer": "Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease: - Published in 1989 by Hepatology International, titled \"Hepatotoxicity of tacrine in Alzheimer's disease: a case report and review of the literature.\" - Includes 1 abstract and 1 article [8139084] - Abstract states that tacrine was administered to 1 patient with Alzheimer's disease, and he developed liver enzyme elevations and liver failure [7510447] - Article discusses the potential mechanisms of hepatotoxicity in Alzheimer's disease, including altered lipid metabolism and oxidative stress [25858345]", "pmids": ["8139084", "7510447", "25858345"], "pmid_titles": {"8139084": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25858345": "(No title fetched)"}, "topk_used": ["7737527", "23334070", "22034058", "8139084", "25871773", "17636619", "19270633", "9808364", "12939598", "7579023", "17883890", "22536363", "7868848", "10325444", "7510447", "15783264", "10796507", "2107926", "7919566", "25858345"], "topk_titles": {"7737527": "Alzheimer's disease: how to give and monitor tacrine therapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22034058": "(No title fetched)", "8139084": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "17636619": "(No title fetched)", "19270633": "(No title fetched)", "9808364": "(No title fetched)", "12939598": "Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "17883890": "Nose-to-brain delivery of tacrine.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7868848": "Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.", "10325444": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "10796507": "Tacrine for Alzheimer's disease.", "2107926": "Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Fran\u00e7ais d'Etude de la Tetrahydroaminoacridine.", "7919566": "Tacrine: first drug approved for Alzheimer's disease.", "25858345": "(No title fetched)"}, "gold_ideal": ["The side effects during tacrine administration in patients with Alzheimer's Disease are:\r\n1) Hepatotoxicity\r\n2) Gastrointestinal (diarrhea, anorexia, dyspepsia, abdominal pain, nausea, vomiting)\r\n3) Mitochondrial impairement"], "gold_exact": [["Hepatotoxicity"], ["Gastrointestinal"], ["diarrhea"], ["anorexia"], ["dyspepsia"], ["abdominal pain"], ["nausea"], ["vomiting"], ["anorexia"], ["Mitochondrial impairement"]]}
{"id": "58a2efec60087bc10a000008", "question": "Which are the consequences of the hyperphosphorylated tau in Alzheimers' Disease?", "answer": "The consequences of the hyperphosphorylated tau in Alzheimers' Disease remain poorly characterized at the early stage of disease before the formation of tau insoluble filaments [19525898] Hyperphosphorylated tau comprises the paired helical filament, whose pathological deposition as neurofibrillary tangles is implicated in Alzheimer's disease, and hyperphosphorylated tau is also implicated in the pathogenesis of other neurodegenerative disorders [16793187]", "pmids": ["19525898", "16793187"], "pmid_titles": {"19525898": "(No title fetched)", "16793187": "(No title fetched)"}, "topk_used": ["9084440", "26258756", "19525898", "17372746", "23640887", "24965601", "37943150", "11052669", "19459590", "20678581", "16793187", "22110363", "22203915", "20678074", "24434253", "7616230", "22536363", "19451179", "23340677", "12214106"], "topk_titles": {"9084440": "Cytoskeletal changes in the brains of mice lacking calcineurin A alpha.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "19525898": "(No title fetched)", "17372746": "Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "37943150": "(No title fetched)", "11052669": "Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins.", "19459590": "(No title fetched)", "20678581": "(No title fetched)", "16793187": "(No title fetched)", "22110363": "The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders.", "22203915": "(No title fetched)", "20678074": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "7616230": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "19451179": "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.", "23340677": "(No title fetched)", "12214106": "beta-Amyloid-Induced Tau Phosphorylation does not Correlate with Degeneration in Cultured Neurons."}, "gold_ideal": ["The consequences of the hyperphosphorylated tau in Alzheimers' Disease is:\n1) The formation of neurofibrillary tangles (NFTs)\n2) Impaired glutamate metabolism\n3) Decreased tau affinity for microtubules binding\n4) Dendritic and axonal instability\n5) Synaptic degeneration\n6) Neuronal loss."], "gold_exact": [["Neurofibrillary tangles formatio", "NFTs", "NFT formation"], ["Impaired glutamate metabolism"], ["Decreased affinity for microtubules binding"], ["Dendritic instability"], ["Axonal instability"], ["Synaptic degeneration"], ["Neuronal loss"]]}
{"id": "58bbb8ae22d3005309000018", "question": "Has whole exome sequencing been performed in Alzheimer patients?", "answer": "Yes, whole exome sequencing has been performed in Alzheimer patients [27822510] The study by [27822510] performed whole-exome sequencing in early-onset Alzheimer disease (EOAD) and late-onset Alzheimer disease (LOAD) families followed by functional studies of select variants [27358062] This study provides evidence for the use of whole-exome sequencing in Alzheimer patients [18620875]", "pmids": ["27822510", "27358062", "18620875"], "pmid_titles": {"27822510": "(No title fetched)", "27358062": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study."}, "topk_used": ["27822510", "26522186", "22153900", "23237904", "22472873", "24958194", "19278690", "18620875", "23150934", "17182990", "37943150", "21971452", "29441009", "27358062", "8237620", "21996556", "19164222", "38021811", "35558050", "24119542"], "topk_titles": {"27822510": "(No title fetched)", "26522186": "(No title fetched)", "22153900": "(No title fetched)", "23237904": "(No title fetched)", "22472873": "(No title fetched)", "24958194": "(No title fetched)", "19278690": "(No title fetched)", "18620875": "Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.", "23150934": "(No title fetched)", "17182990": "PET of brain amyloid and tau in mild cognitive impairment.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "29441009": "(No title fetched)", "27358062": "(No title fetched)", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19164222": "Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "35558050": "(No title fetched)", "24119542": "(No title fetched)"}, "gold_ideal": ["Yes, numerous whole exome sequencing studies of ALzheimer patients have been conducted."], "gold_exact": ["yes"]}
{"id": "58a2c77a60087bc10a000002", "question": "What is the role of gamma-secreatase complex in Alzheimer's Disease?", "answer": "Question: What is the role of gamma-secreatase complex in Alzheimer's Disease? [19299585] : 1 [18320103] Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease [18393798]", "pmids": ["19299585", "18320103", "18393798"], "pmid_titles": {"19299585": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene].", "18393798": "(No title fetched)"}, "topk_used": ["20445084", "19299585", "23316412", "16804564", "17298085", "19958468", "19376115", "18038124", "22122056", "20035833", "18393798", "20600609", "16944319", "16675392", "23379308", "20129170", "15992373", "27567808", "17560791", "18320103"], "topk_titles": {"20445084": "(No title fetched)", "19299585": "(No title fetched)", "23316412": "(No title fetched)", "16804564": "(No title fetched)", "17298085": "(No title fetched)", "19958468": "(No title fetched)", "19376115": "(No title fetched)", "18038124": "(No title fetched)", "22122056": "(No title fetched)", "20035833": "(No title fetched)", "18393798": "(No title fetched)", "20600609": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "16675392": "(No title fetched)", "23379308": "(No title fetched)", "20129170": "(No title fetched)", "15992373": "(No title fetched)", "27567808": "(No title fetched)", "17560791": "(No title fetched)", "18320103": "[Evaluation of amyloid-beta by the E280A mutation in presenilin gene]."}, "gold_ideal": ["The gamma-secretase complex has a decisive role in the development of Alzheimer's disease, as it cleaves a precursor protein to create the amyloid beta peptide whose aggregates form the senile plaques encountered in the brains of patients. Gamma-secretase is a member of the intramembrane-cleaving proteases which process their transmembrane substrates within the bilayer."], "gold_exact": ["cleaves a precursor protein to create the amyloid beta peptide"]}
{"id": "58b6cd3222d300530900000d", "question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answer": "Among three isoforms, the apoE4 is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD), as per the evidence provided in the question [16903824]", "pmids": ["16903824"], "pmid_titles": {"16903824": "(No title fetched)"}, "topk_used": ["26427386", "24754513", "16903824", "15570172", "10949525", "20531185", "19033669", "18823563", "18359298", "11701639", "8726460", "16540478", "15475580", "19549280", "22393530", "15649697", "7846048", "21907569", "25871773", "8367470"], "topk_titles": {"26427386": "Apolipoprotein E Isoforms and AMD.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "16903824": "(No title fetched)", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "10949525": "Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "19033669": "apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.", "18823563": "(No title fetched)", "18359298": "(No title fetched)", "11701639": "(No title fetched)", "8726460": "(No title fetched)", "16540478": "(No title fetched)", "15475580": "(No title fetched)", "19549280": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "21907569": "Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "8367470": "Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease."}, "gold_ideal": ["The ApoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD)."], "gold_exact": ["ApoE4 isoform", "Apolipoprotein E4 isoform"]}
{"id": "5a7d51dafaa1ab7d2e000017", "question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answer": "Hepatotoxic effects of tacrine administration in Alzheimer's disease patients were investigated using evidence from 3 articles [8139084] The study found that tacrine was associated with hepatotoxicity, particularly in patients with advanced Alzheimer's disease [9808364] However, the exact mechanism of this effect is not yet fully understood [17883890]", "pmids": ["8139084", "9808364", "17883890"], "pmid_titles": {"8139084": "(No title fetched)", "9808364": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine."}, "topk_used": ["15783264", "24760109", "24760112", "23861639", "23334070", "37943150", "29441009", "25115546", "37488880", "19278690", "21996556", "9808364", "37490245", "35558050", "17883890", "38021811", "36281662", "27223100", "20154508", "8139084"], "topk_titles": {"15783264": "Accounting for individual differences in risk of Alzheimer disease.", "24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "25115546": "(No title fetched)", "37488880": "(No title fetched)", "19278690": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "9808364": "(No title fetched)", "37490245": "(No title fetched)", "35558050": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "36281662": "(No title fetched)", "27223100": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "8139084": "(No title fetched)"}, "gold_ideal": ["IVIG is administered intravenously."], "gold_exact": ["Intravenous"]}
{"id": "5a7d54adfaa1ab7d2e000019", "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?", "answer": "Yes, clinical trials of intravenous immunoglobulin for Alzheimer's disease have been conducted [24760112] These trials are ongoing and involve administering a specific type of immunoglobulin (IVIg) to patients with Alzheimer's disease [23861639] The evidence presented in the given material suggests that IVIg may be an effective treatment option for this condition [23334070]", "pmids": ["24760112", "23861639", "23334070"], "pmid_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["24760112", "23861639", "24760109", "23334070", "37943150", "25115546", "19278690", "29441009", "29397980", "15783264", "27223100", "36281662", "37490245", "38021811", "23883379", "20122289", "37414156", "37488880", "21996556", "24983746"], "topk_titles": {"24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "24760109": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37943150": "(No title fetched)", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "29441009": "(No title fetched)", "29397980": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "27223100": "(No title fetched)", "36281662": "(No title fetched)", "37490245": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "23883379": "(No title fetched)", "20122289": "Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.", "37414156": "(No title fetched)", "37488880": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)"}, "gold_ideal": ["Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5a7357e63b9d13c708000001", "question": "Is there an RNAi drug being developed to treat amyloidosis?", "answer": "Yes, there is an RNAi drug being developed to treat amyloidosis [23334070] The investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis is patisiran, which is an RNAi therapeutic designed to target amyloid beta (A\u03b2) proteins [28893208] Patisiran has been shown to be effective in preclinical models of hATTR amyloidosis, and clinical trials are currently underway to evaluate its safety and efficacy in patients with hATTR amyloidosis [36336119]", "pmids": ["23334070", "28893208", "36336119"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "28893208": "(No title fetched)", "36336119": "(No title fetched)"}, "topk_used": ["36336119", "37599395", "19363993", "28922609", "28893208", "21624562", "23053137", "20360050", "22815077", "20942790", "19324376", "15014128", "20929585", "23334070", "37490245", "37456349", "23527322", "28749667", "37389302", "21987394"], "topk_titles": {"36336119": "(No title fetched)", "37599395": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28922609": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "23053137": "(No title fetched)", "20360050": "Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "37490245": "(No title fetched)", "37456349": "(No title fetched)", "23527322": "(No title fetched)", "28749667": "(No title fetched)", "37389302": "(No title fetched)", "21987394": "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab."}, "gold_ideal": ["Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis."], "gold_exact": ["yes"]}
{"id": "5a735b383b9d13c708000002", "question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answer": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality [28893208] It is an RNAi therapeutic that targets the production of amyloid beta (A\u03b2) peptides, which are implicated in the pathogenesis of hATTR amyloidosis [26243339] Patisiran has shown promising results in preclinical models and clinical trials, and it is currently being evaluated in a Phase III trial for the treatment of hATTR amyloidosis [33841597]", "pmids": ["28893208", "26243339", "33841597"], "pmid_titles": {"28893208": "(No title fetched)", "26243339": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["37599395", "28893208", "36336119", "26299174", "23053137", "19013120", "8113408", "26243339", "28802308", "29142973", "25331409", "23551149", "33841597", "28922609", "15523923", "8097946", "20558869", "19073821", "37389302", "37456349"], "topk_titles": {"37599395": "(No title fetched)", "28893208": "(No title fetched)", "36336119": "(No title fetched)", "26299174": "(No title fetched)", "23053137": "(No title fetched)", "19013120": "(No title fetched)", "8113408": "(No title fetched)", "26243339": "(No title fetched)", "28802308": "(No title fetched)", "29142973": "(No title fetched)", "25331409": "(No title fetched)", "23551149": "(No title fetched)", "33841597": "(No title fetched)", "28922609": "(No title fetched)", "15523923": "(No title fetched)", "8097946": "(No title fetched)", "20558869": "[Gelsolin - variety of structure and functions].", "19073821": "(No title fetched)", "37389302": "(No title fetched)", "37456349": "(No title fetched)"}, "gold_ideal": ["Patisiran.", "The investigational RNAi drug in development for the treatment of hereditary amyloidosis is patisiran."], "gold_exact": ["Patisiran"]}
{"id": "5a774431faa1ab7d2e000004", "question": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "answer": "The Fyn kinase, which is involved in the amyloidogenic processing of \u03b2-amyloid precursor protein (A\u03b2), is a promising target for Alzheimer's disease due to its role in the amyloidogenic processing of this protein [23316412] Specifically, the \u03b3-secretase complex, which is composed of Fyn and other proteins, is a promising target in Alzheimer's disease because it plays a critical role in the amyloidogenic processing of A\u03b2 [23847530] The \u03b3-secretase complex has been shown to be a promising target for disease-modifying therapeutic strategies like passive immunotherapy with anti-A\u03b2 mAbs, as it has been shown to reduce A\u03b2 levels in animal models of AD [24434253]", "pmids": ["23316412", "23847530", "24434253"], "pmid_titles": {"23316412": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?"}, "topk_used": ["28709498", "25874001", "19278690", "23316412", "21971452", "23847530", "29441009", "19881909", "37943150", "19228370", "22122056", "15783264", "37488880", "37490245", "24434253", "19958468", "22292124", "28649604", "22203915", "22009441"], "topk_titles": {"28709498": "(No title fetched)", "25874001": "(No title fetched)", "19278690": "(No title fetched)", "23316412": "(No title fetched)", "21971452": "(No title fetched)", "23847530": "Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review.", "29441009": "(No title fetched)", "19881909": "MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders.", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "22122056": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "37490245": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "19958468": "(No title fetched)", "22292124": "Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.", "28649604": "(No title fetched)", "22203915": "(No title fetched)", "22009441": "(No title fetched)"}, "gold_ideal": ["Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD."], "gold_exact": []}
{"id": "5a7d535ffaa1ab7d2e000018", "question": "What does the human IVIG treatment for Alzheimer's disease contain?", "answer": "Adult human nerve cells contain tau protein, a phosphorylated microtubule-associated protein, that is hyperphosphorylated in the fetus and in patients with Alzheimer's disease [7666054] This hyperphosphorylation is thought to contribute to the pathogenesis of this devastating neurodegenerative disorder [23861639]", "pmids": ["7666054", "23861639"], "pmid_titles": {"7666054": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins."}, "topk_used": ["24760109", "24760112", "23861639", "17883890", "23334070", "25115546", "19278690", "20929585", "37943150", "21971452", "7666054", "37264659", "35558050", "15783264", "37488880", "22203915", "21996556", "24983746", "19299585", "23378928"], "topk_titles": {"24760109": "(No title fetched)", "24760112": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "17883890": "Nose-to-brain delivery of tacrine.", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25115546": "(No title fetched)", "19278690": "(No title fetched)", "20929585": "The biochemical aftermath of anti-amyloid immunotherapy.", "37943150": "(No title fetched)", "21971452": "(No title fetched)", "7666054": "(No title fetched)", "37264659": "(No title fetched)", "35558050": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37488880": "(No title fetched)", "22203915": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "24983746": "(No title fetched)", "19299585": "(No title fetched)", "23378928": "Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes."}, "gold_ideal": ["Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors."], "gold_exact": []}
{"id": "5a6a02a3b750ff4455000021", "question": "What protein is the most common cause of hereditary  renal amyloidosis?", "answer": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis [25331409] These mutations lead to the production of abnormal proteins that accumulate in the kidneys and other organs, leading to renal failure and death [19363993] The most common mutations involve changes in the A\u03b1-chain gene, which encodes the fibrinogen A\u03b1-chain protein [19073821]", "pmids": ["25331409", "19363993", "19073821"], "pmid_titles": {"25331409": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "19073821": "(No title fetched)"}, "topk_used": ["25331409", "19013120", "29142973", "26299174", "19073821", "23551149", "14572915", "33023198", "8113408", "8097946", "9389696", "37556728", "15523923", "28922609", "19363993", "37599395", "37489069", "28646538", "37905874", "23552370"], "topk_titles": {"25331409": "(No title fetched)", "19013120": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "19073821": "(No title fetched)", "23551149": "(No title fetched)", "14572915": "(No title fetched)", "33023198": "(No title fetched)", "8113408": "(No title fetched)", "8097946": "(No title fetched)", "9389696": "(No title fetched)", "37556728": "(No title fetched)", "15523923": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "37489069": "(No title fetched)", "28646538": "(No title fetched)", "37905874": "(No title fetched)", "23552370": "(No title fetched)"}, "gold_ideal": ["The most common cause of hereditary  renal amyloidosis is over expression of a mutant form of the Fibrinogen A Alpha protein"], "gold_exact": ["Fibrinogen A Alpha protein"]}
{"id": "5a772e9dfaa1ab7d2e000001", "question": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "answer": "Yes, saracatinib was being considered as a treatment for Alzheimer's disease in November 2017 based on the provided evidence [21996556] The phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease was conducted in November 2017, and the study aimed to evaluate the safety, tolerability, and central nervous system availability of AZD0530 in patients with Al [25874001] The study was a phase Ib multiple ascending dose study and was conducted in multiple ascending doses [23334070]", "pmids": ["21996556", "25874001", "23334070"], "pmid_titles": {"21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "25874001": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study."}, "topk_used": ["25874001", "17883890", "37943150", "29441009", "15783264", "19278690", "21971452", "24434253", "36281662", "23861639", "37488880", "23334070", "20154508", "37490245", "21996556", "19228370", "38075821", "35558050", "38021811", "22536363"], "topk_titles": {"25874001": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "37943150": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "36281662": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "37490245": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "35558050": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation."}, "gold_ideal": ["Yes, saracatinib is being studied as a treatment against Alzheimer's Disease. A clinical Phase Ib study has been completed, and a clinical Phase IIa study is ongoing."], "gold_exact": ["yes"]}
{"id": "5a6e47b1b750ff4455000049", "question": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "answer": "Yes, overproduction of transthyretin is associated with amyloidosis associated neuropathy [26243339] Dominantly inherited transthyretin mutations causing accelerated amyloid deposition are responsible for this association [28920433] Hereditary transthyretin amyloidosis (ATTR) is usually characterized by a progressive peripheral and autonomic neuropathy, often with associated cardiac failure, and is due to dominantly inherited transthyretin mutations causing accelerated amyloid deposition [33841597]", "pmids": ["26243339", "28920433", "33841597"], "pmid_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "33841597": "(No title fetched)"}, "topk_used": ["26243339", "28920433", "28802308", "28922609", "19363993", "37599395", "28646538", "37456349", "33023198", "33841597", "25783987", "35892582", "15523923", "32093040", "27919414", "28893208", "21624562", "37888916", "35558050", "38075821"], "topk_titles": {"26243339": "(No title fetched)", "28920433": "(No title fetched)", "28802308": "(No title fetched)", "28922609": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "37599395": "(No title fetched)", "28646538": "(No title fetched)", "37456349": "(No title fetched)", "33023198": "(No title fetched)", "33841597": "(No title fetched)", "25783987": "(No title fetched)", "35892582": "(No title fetched)", "15523923": "(No title fetched)", "32093040": "(No title fetched)", "27919414": "(No title fetched)", "28893208": "(No title fetched)", "21624562": "(No title fetched)", "37888916": "(No title fetched)", "35558050": "(No title fetched)", "38075821": "(No title fetched)"}, "gold_ideal": ["Yes, an overproduction of transthyretin is associated with amyloidosis associated neuropathy.", "Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a disease caused by the deposit of abnormal transthyretin on tissues, mainly nerves"], "gold_exact": ["yes"]}
{"id": "5a70e1d999e2c3af26000007", "question": "Is Solanezumab effective for Alzheimer's Disease?", "answer": "Yes, Solanezumab is effective for Alzheimer's Disease based on the evidence from the recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, which raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkins [28649604]", "pmids": ["28649604"], "pmid_titles": {"28649604": "(No title fetched)"}, "topk_used": ["23334070", "7510447", "15649697", "28649604", "23624169", "23334069", "20154508", "20375655", "7579023", "22536363", "37490245", "28593105", "25871773", "37831471", "37414156", "26238576", "23582316", "21784350", "21504387", "21971452"], "topk_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "28649604": "(No title fetched)", "23624169": "(No title fetched)", "23334069": "Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "20375655": "Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "37490245": "(No title fetched)", "28593105": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "37831471": "(No title fetched)", "37414156": "(No title fetched)", "26238576": "(No title fetched)", "23582316": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "21504387": "(No title fetched)", "21971452": "(No title fetched)"}, "gold_ideal": ["No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."], "gold_exact": ["no"]}
{"id": "5a9d7caa1d1251d03b00001e", "question": "What is Alzheimers disease resilience?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] These neurodegenerative diseases primarily affect individuals aged 65 or above, characterized by the amyloid accumulation in the brains of patients with Alzheimer's disease [38021811]", "pmids": ["22009441", "38021811"], "pmid_titles": {"22009441": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management."}, "topk_used": ["37943150", "28025282", "37488880", "36281662", "29441009", "24132372", "29298722", "38075821", "23624169", "37264659", "32183348", "35558050", "22009441", "15649697", "27358062", "21715616", "22203915", "38021811", "29080524", "10679843"], "topk_titles": {"37943150": "(No title fetched)", "28025282": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "29441009": "(No title fetched)", "24132372": "Amyloid and neurodegeneration: converging and diverging paths.", "29298722": "(No title fetched)", "38075821": "(No title fetched)", "23624169": "(No title fetched)", "37264659": "(No title fetched)", "32183348": "(No title fetched)", "35558050": "(No title fetched)", "22009441": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "27358062": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "22203915": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "29080524": "(No title fetched)", "10679843": "(No title fetched)"}, "gold_ideal": ["Some 30 to 50% of older individuals who harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia."], "gold_exact": []}
{"id": "5a9d8d691d1251d03b000020", "question": "What is the association of the protein RAB10 and Alzheimers disease?", "answer": "The association of the protein RAB10 and Alzheimers disease is supported by evidence from cerebro-spinal fluid (CSF), which shows that it is the second most abundant protein and is considered an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication [19363993] Additionally, since TTR is a highly amyloidogenic protein because it contains a beta-sheet structure, it becomes a precursor protein in familial amyloidotic polyneuropathy (FAP) [32093040] Furthermore, Alzheimer's disease is associated with amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles, which are accumulated with hyperphosphorylated Tau protein [37943150]", "pmids": ["19363993", "32093040", "37943150"], "pmid_titles": {"19363993": "[Transthyretin: it's miracle function and pathogenesis].", "32093040": "(No title fetched)", "37943150": "(No title fetched)"}, "topk_used": ["37943150", "29441009", "35558050", "37488880", "36281662", "21996556", "37264659", "19278690", "32093040", "21705182", "19363993", "21971452", "15783264", "14572915", "22009441", "29574591", "19228370", "38075821", "24633805", "22203915"], "topk_titles": {"37943150": "(No title fetched)", "29441009": "(No title fetched)", "35558050": "(No title fetched)", "37488880": "(No title fetched)", "36281662": "(No title fetched)", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "37264659": "(No title fetched)", "19278690": "(No title fetched)", "32093040": "(No title fetched)", "21705182": "(No title fetched)", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "21971452": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "14572915": "(No title fetched)", "22009441": "(No title fetched)", "29574591": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "38075821": "(No title fetched)", "24633805": "(No title fetched)", "22203915": "(No title fetched)"}, "gold_ideal": ["The genes SEC22B, RAB10 and FLT1 may be potential biomarkers of AD."], "gold_exact": ["RAB10 may be potential biomarkers of AD"]}
{"id": "5a9d96564e03427e73000001", "question": "List major risk factors for Alzheimer's disease. ", "answer": "1 [37943150] Cardiovascular risk factors, especially hypertension, are major risk factors for Alzheimer's disease (AD) [28435465] 2 [35558050]", "pmids": ["37943150", "28435465", "35558050"], "pmid_titles": {"37943150": "(No title fetched)", "28435465": "(No title fetched)", "35558050": "(No title fetched)"}, "topk_used": ["28435465", "28025282", "14614898", "28272510", "24633805", "19549280", "28884281", "15783264", "22529838", "22393530", "25871773", "20531185", "21715616", "21996556", "29441009", "23855982", "23420460", "23380991", "35558050", "37943150"], "topk_titles": {"28435465": "(No title fetched)", "28025282": "(No title fetched)", "14614898": "(No title fetched)", "28272510": "(No title fetched)", "24633805": "(No title fetched)", "19549280": "(No title fetched)", "28884281": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22529838": "Alzheimer's disease: a clinical practice-oriented review.", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "21996556": "Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly.", "29441009": "(No title fetched)", "23855982": "(No title fetched)", "23420460": "Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough.", "23380991": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)"}, "gold_ideal": ["Apolipoprotein E4\ntype 2 diabetes\nClusterin\nHypertension\nadvancing age\nobesity"], "gold_exact": [["Apolipoprotein E4"], ["type 2 diabetes"], ["Clusterin"], ["Hypertension"], ["advancing age"], ["obesity"]]}
{"id": "5c5723a007647bbc4b000019", "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?", "answer": "Yes, yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [23379365] Yeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions [26915272]", "pmids": ["23379365", "26915272"], "pmid_titles": {"23379365": "(No title fetched)", "26915272": "(No title fetched)"}, "topk_used": ["26915272", "23379365", "17514901", "23045389", "28932898", "25631286", "28148884", "29698650", "23077577", "15783264", "22052352", "29330303", "19228370", "23861639", "29441009", "19278690", "37943150", "16944319", "20942790", "8726460"], "topk_titles": {"26915272": "(No title fetched)", "23379365": "(No title fetched)", "17514901": "(No title fetched)", "23045389": "(No title fetched)", "28932898": "(No title fetched)", "25631286": "(No title fetched)", "28148884": "(No title fetched)", "29698650": "(No title fetched)", "23077577": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "22052352": "(No title fetched)", "29330303": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "29441009": "(No title fetched)", "19278690": "(No title fetched)", "37943150": "(No title fetched)", "16944319": "The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "8726460": "(No title fetched)"}, "gold_ideal": ["infectious proteins) were discovered by their outr\u00e9 genetic properties and have become important models for an array of human prion and amyloid diseases.", "Yeast prions have become important models for the study of the basic mechanisms underlying human amyloid diseases and normal yeast cells can eliminate the large majority of prion variants arising.", "Endogenous yeast amyloids that control heritable traits and are frequently used as models for human amyloid diseases are termed yeast prions", "These infectious yeast amyloidoses are outstanding models for the many common human amyloid-based diseases that are increasingly found to have some infectious characteristics."], "gold_exact": ["yes"]}
{"id": "5c6b82a17c78d6947100002f", "question": "Is verubecestat effective for Alzheimer\u2019s Disease?", "answer": "Yes, verubecestat did not show efficacy in reducing cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease [29719179] This was associated with treatment-related adverse events [24983746] Lessons that can be learnt from the failure of verubecestat in Alzheimer 's disease include the importance of conducting rigorous clinical trials to evaluate the safety and efficacy of new treatments, the need for caution when interpreting results, and the importance of adhering to established guidelines for clinical r [31423903]", "pmids": ["29719179", "24983746", "31423903"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "31423903": "(No title fetched)"}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "33049114", "28749667", "15649697", "7510447", "7579023", "23624169", "20154508", "22536363", "25871773", "23883379", "24983746", "27567808", "37943150", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "23883379": "(No title fetched)", "24983746": "(No title fetched)", "27567808": "(No title fetched)", "37943150": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease."], "gold_exact": ["no"]}
{"id": "5c53191a7e3cb0e231000016", "question": "What periodontal disease associated bacteria is also associated with Alzheimer's disease?", "answer": "Question: What periodontal disease associated bacteria is also associated with Alzheimer's disease? [29046054] : 1 [23340677] The apolipoprotein E (APOE) E4 allele is associated with Alzheimer's disease, cardiovascular disease, and decreased longevity [8782820]", "pmids": ["29046054", "23340677", "8782820"], "pmid_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "23340677": "(No title fetched)", "8782820": "(No title fetched)"}, "topk_used": ["29046054", "37943150", "14572915", "36281662", "18823563", "24099003", "35558050", "28435465", "22009441", "21705182", "29441009", "37488880", "27358062", "16793187", "20826658", "8782820", "29574591", "37556728", "33513738", "23340677"], "topk_titles": {"29046054": "Porphyromonas gingivalis lipopolysaccharide stimulation in human periodontal ligament stem cells: role of epigenetic modifications to the inflammation.", "37943150": "(No title fetched)", "14572915": "(No title fetched)", "36281662": "(No title fetched)", "18823563": "(No title fetched)", "24099003": "(No title fetched)", "35558050": "(No title fetched)", "28435465": "(No title fetched)", "22009441": "(No title fetched)", "21705182": "(No title fetched)", "29441009": "(No title fetched)", "37488880": "(No title fetched)", "27358062": "(No title fetched)", "16793187": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "8782820": "(No title fetched)", "29574591": "(No title fetched)", "37556728": "(No title fetched)", "33513738": "(No title fetched)", "23340677": "(No title fetched)"}, "gold_ideal": ["Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD).", "Among bacteria special attention is focused on spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis or Treponema denticola that could cause chronic periodontitis and possibly contribute to the clinical onset of AD."], "gold_exact": ["Porphyromonas gingivalis"]}
{"id": "5c73acf27c78d6947100008a", "question": "Is Semagacestat effective for treatment of Alzheimer's disease?", "answer": "Yes, Semagacestat is an experimental drug for the treatment of Alzheimer's disease [23785331] A phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [23883379] However, a phase 3 trial of semagacestat for treatment of Alzheimer's disease found that it did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability [29719179]", "pmids": ["23785331", "23883379", "29719179"], "pmid_titles": {"23785331": "(No title fetched)", "23883379": "(No title fetched)", "29719179": "(No title fetched)"}, "topk_used": ["20154508", "27567808", "24983746", "23883379", "17883890", "23785331", "23334070", "25871773", "21149978", "28978478", "21971452", "7510447", "22122056", "26064192", "23196551", "22536363", "21501112", "29719179", "21784350", "29461065"], "topk_titles": {"20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "27567808": "(No title fetched)", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "23785331": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "21149978": "(No title fetched)", "28978478": "(No title fetched)", "21971452": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "22122056": "(No title fetched)", "26064192": "(No title fetched)", "23196551": "(No title fetched)", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "21501112": "(No title fetched)", "29719179": "(No title fetched)", "21784350": "Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.", "29461065": "(No title fetched)"}, "gold_ideal": ["No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections."], "gold_exact": ["no"]}
{"id": "5c72a5ca7c78d6947100006d", "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?", "answer": "As of February 2019, major brain gangliosides have been targeted for the treatment of Alzheimer's disease through the approval of lecanemab, a monoclonal antibody specifically designed to target beta-amyloid [23334070] However, additional research is needed to determine the efficacy and safety of this approach [20154508] While there is currently insufficient evidence to support the use of gangliosides as a therapeutic agent against stroke and Alzheimer's disease, further studies may provide valuable insights into their potential benefits [7997071]", "pmids": ["23334070", "20154508", "7997071"], "pmid_titles": {"23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7997071": "(No title fetched)"}, "topk_used": ["7997071", "29441009", "15783264", "37943150", "19278690", "21971452", "24434253", "23210837", "37902139", "23861639", "37488880", "19228370", "36281662", "19299585", "23334070", "21274438", "22203915", "8180825", "20154508", "23624169"], "topk_titles": {"7997071": "(No title fetched)", "29441009": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "37943150": "(No title fetched)", "19278690": "(No title fetched)", "21971452": "(No title fetched)", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "37902139": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "37488880": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "36281662": "(No title fetched)", "19299585": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "21274438": "(No title fetched)", "22203915": "(No title fetched)", "8180825": "Alzheimer disease: correlation of cerebro-spinal fluid and brain ubiquitin levels.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "23624169": "(No title fetched)"}, "gold_ideal": ["As of Feb 2019, major brain gangliosides are proposed as a target for the treatment of Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5c8857e975a4a5d219000009", "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?", "answer": "Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease due to their dual risk factor status to atherosclerosis and Alzheimer's disease [16540478] The evidence presented in the given material suggests that APOE-epsilon3 is a longevity gene, while APOE-epsilon4 is a dual risk factor to atherosclerosis and Alzheimer's disease [18823563] However, further research is needed to confirm these findings [24754513]", "pmids": ["16540478", "18823563", "24754513"], "pmid_titles": {"16540478": "(No title fetched)", "18823563": "(No title fetched)", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease."}, "topk_used": ["27683909", "24754513", "22965147", "25871773", "26427386", "15649697", "16540478", "8726460", "18823563", "15783264", "15475580", "22393530", "15570172", "20531185", "7846048", "24633805", "15014128", "12767492", "16903824", "28949931"], "topk_titles": {"27683909": "Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice.", "24754513": "The role of apolipoprotein E in neurodegeneration and cardiovascular disease.", "22965147": "(No title fetched)", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "26427386": "Apolipoprotein E Isoforms and AMD.", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "16540478": "(No title fetched)", "8726460": "(No title fetched)", "18823563": "(No title fetched)", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "15475580": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "15570172": "ApoE isoform affects LTP in human targeted replacement mice.", "20531185": "Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.", "7846048": "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.", "24633805": "(No title fetched)", "15014128": "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "16903824": "(No title fetched)", "28949931": "(No title fetched)"}, "gold_ideal": ["Yes, apoE mimetics are being considered as a treatment against Alzheimer's disease, and  they have been shown to protect AD mouse models against these AD-like features."], "gold_exact": ["yes"]}
{"id": "5c890c3375a4a5d21900000e", "question": "Can oleuropein aglycone interfere with amyloid aggregation?", "answer": "Yes, oleuropein aglycone interferes with amyloid aggregation [29571746] : [20154508] Compounds that interfere with proteases regulating Abeta formation from amyloid precursor protein (APP) are also actively pursued [20154508] [21715616] A\u03b2 is thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state [21715616]", "pmids": ["29571746", "20154508", "21715616"], "pmid_titles": {"29571746": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities."}, "topk_used": ["29571746", "20826658", "22122056", "15649697", "33023198", "21768095", "21715616", "20154508", "19363993", "28749667", "29080524", "24965601", "32093040", "22393530", "21971452", "20942790", "23293020", "37905874", "37490245", "36856953"], "topk_titles": {"29571746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "22122056": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33023198": "(No title fetched)", "21768095": "(No title fetched)", "21715616": "Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-\u03b2 accumulation and independently accelerates the development of tau abnormalities.", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "19363993": "[Transthyretin: it's miracle function and pathogenesis].", "28749667": "(No title fetched)", "29080524": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.", "32093040": "(No title fetched)", "22393530": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.", "21971452": "(No title fetched)", "20942790": "Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease.", "23293020": "Levels of soluble apolipoprotein E/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.", "37905874": "(No title fetched)", "37490245": "(No title fetched)", "36856953": "(No title fetched)"}, "gold_ideal": ["Yes, oleuropein aglycone interferes in vitro and in vivo with amyloid aggregates."], "gold_exact": ["yes"]}
{"id": "5c891d5075a4a5d219000011", "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?", "answer": "Yes, Crocus sativus compounds have been shown to improve cognitive function in Alzheimer's disease (AD) patients [28471166] Previous evidence suggested that Crocus sativus is linked to improving cognitive function in AD patients [22546352] However, additional evidence from retrieved abstracts suggests that this effect may be due to the dual risk factor of APOE-epsilon4 [16540478]", "pmids": ["28471166", "22546352", "16540478"], "pmid_titles": {"28471166": "(No title fetched)", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "16540478": "(No title fetched)"}, "topk_used": ["28471166", "23334070", "22536363", "15783264", "7510447", "19278690", "21705182", "35558050", "37943150", "24983746", "20826658", "37490245", "29441009", "21971452", "37905874", "12767492", "17662457", "22546352", "32183293", "16540478"], "topk_titles": {"28471166": "(No title fetched)", "23334070": "Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "15783264": "Accounting for individual differences in risk of Alzheimer disease.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "19278690": "(No title fetched)", "21705182": "(No title fetched)", "35558050": "(No title fetched)", "37943150": "(No title fetched)", "24983746": "(No title fetched)", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "37490245": "(No title fetched)", "29441009": "(No title fetched)", "21971452": "(No title fetched)", "37905874": "(No title fetched)", "12767492": "Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study.", "17662457": "An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.", "22546352": "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.", "32183293": "(No title fetched)", "16540478": "(No title fetched)"}, "gold_ideal": ["Yes, it has been observed that Crocus sativus extracts and compounds have a positive effect against Alzheimer's disease."], "gold_exact": ["yes"]}
{"id": "5ca0848aecadf2e73f000044", "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?", "answer": "Yes, there are anti-amyloid antibody approved as drug for Alzheimer's disease treatment [38095822] These include Lecanemab (approved in 2023) and aducanumab (approved in 2021) for the treatment of Alzheimer's disease patients, and donanemab (approved in 2022) for mild cognitive impairment or mild dementia [37902139] These drugs work by targeting beta-amyloid, which is a key component of Alzheimer's disease [37251789]", "pmids": ["38095822", "37902139", "37251789"], "pmid_titles": {"38095822": "(No title fetched)", "37902139": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint."}, "topk_used": ["37414156", "37831471", "37060386", "38021811", "37902139", "17883890", "7579023", "38095822", "19228370", "37490245", "37389302", "37682322", "37251789", "37955845", "23861639", "22815077", "8237620", "38067098", "23210837", "19278690"], "topk_titles": {"37414156": "(No title fetched)", "37831471": "(No title fetched)", "37060386": "(No title fetched)", "38021811": "From Symptomatic Treatment to Disease Modification: A Turning Point in Alzheimer's Disease Management.", "37902139": "(No title fetched)", "17883890": "Nose-to-brain delivery of tacrine.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "38095822": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "37490245": "(No title fetched)", "37389302": "(No title fetched)", "37682322": "(No title fetched)", "37251789": "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.", "37955845": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "22815077": "Disease modifying drugs targeting \u03b2-amyloid.", "8237620": "An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease.", "38067098": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "19278690": "(No title fetched)"}, "gold_ideal": ["No new drugs have been approved during the past 15 years; and the available medications are not cost-effective."], "gold_exact": ["no"]}
{"id": "5e6e767e51b80c9423000006", "question": "What is known about autosomal dominant Alzheimer\u2019s disease?", "answer": "Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [22009441] 1 [10214944] Alzheimer's disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and Pick's disease (PiD) are commonly known as tauopathies [29441009]", "pmids": ["22009441", "10214944", "29441009"], "pmid_titles": {"22009441": "(No title fetched)", "10214944": "(No title fetched)", "29441009": "(No title fetched)"}, "topk_used": ["37943150", "35558050", "29182052", "36687366", "37264659", "22009441", "29142973", "26299174", "28802308", "33513738", "37488880", "37556728", "29441009", "36281662", "22203915", "28949931", "29574591", "38075821", "21705182", "10214944"], "topk_titles": {"37943150": "(No title fetched)", "35558050": "(No title fetched)", "29182052": "(No title fetched)", "36687366": "(No title fetched)", "37264659": "(No title fetched)", "22009441": "(No title fetched)", "29142973": "(No title fetched)", "26299174": "(No title fetched)", "28802308": "(No title fetched)", "33513738": "(No title fetched)", "37488880": "(No title fetched)", "37556728": "(No title fetched)", "29441009": "(No title fetched)", "36281662": "(No title fetched)", "22203915": "(No title fetched)", "28949931": "(No title fetched)", "29574591": "(No title fetched)", "38075821": "(No title fetched)", "21705182": "(No title fetched)", "10214944": "(No title fetched)"}, "gold_ideal": ["The first autosomal dominant mutation in the amyloid precursor protein (APP) gene was described in 1991. Later, AD was also associated with mutated early-onset (presenilin 1/2, PSEN1/2 and APP) and late-onset (apolipoprotein E, ApoE) genes. Genome-wide association and linkage analysis studies with identified multiple genomic areas have implications for the treatment of AD.\nThe Dominantly Inherited Alzheimer Network, an international family-clustered registry to study autosomal dominant Alzheimer disease which is a rare form of Alzheimer disease caused by mutations in any of the three genes including the amyloid precursor protein, presenilin 1 and presenilin 2."], "gold_exact": []}
{"id": "5e3c841148dab47f26000002", "question": "Before 2019, what neurologic diseases are associated with the tau protein?", "answer": "In several neurodegenerative diseases, including Alzheimer disease, the neuronal microtubule-associated protein tau becomes hyperphosphorylated, accumulates in the somatodendritic compartment, and aggregates into insoluble filaments [19525898] This leads to the pathophysiology of AD, which is characterized by memory decline and cognitive impairment [37943150] Hyperphosphorylated Tau protein is a hallmark of AD, and its accumulation is related to amyloid-\u03b2 (A\u03b2) plaques and neurofibrillary tangles [24965601]", "pmids": ["19525898", "37943150", "24965601"], "pmid_titles": {"19525898": "(No title fetched)", "37943150": "(No title fetched)", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "topk_used": ["37905874", "37943150", "19228370", "25031639", "24434253", "29441009", "23861639", "26258756", "23340677", "23210837", "20826658", "24788298", "20154508", "15450610", "19525898", "11204323", "8960316", "19324376", "23640887", "24965601"], "topk_titles": {"37905874": "(No title fetched)", "37943150": "(No title fetched)", "19228370": "Recent developments in Alzheimer's disease therapeutics.", "25031639": "Acetylation: a new key to unlock tau's role in neurodegeneration.", "24434253": "New treatment strategies for Alzheimer's disease: is there a hope?", "29441009": "(No title fetched)", "23861639": "Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.", "26258756": "Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease.", "23340677": "(No title fetched)", "23210837": "Current advances in the treatment of Alzheimer's disease: focused on considerations targeting A\u03b2 and tau.", "20826658": "Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.", "24788298": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "15450610": "(No title fetched)", "19525898": "(No title fetched)", "11204323": "[Apolipoprotein E(ApoE)and tau protein in Alzheimer type dementia].", "8960316": "Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment.", "19324376": "Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection.", "23640887": "Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.", "24965601": "Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution."}, "gold_ideal": ["Tau proteins are involved in the pathogenesis of multiple sclerosis and amyotrophic lateral sclerosis.", "Both Alzheimer's Disease and Multiple Sclerosis are associated with tau protein"], "gold_exact": [["Alzheimer's"], ["Multiple Sclerosis"], ["AML"], ["Pick's disease (PiD)"], ["parkinsonism linked to chromosome 17 (FTDP-17)"], ["progressive supranuclear palsy (PSP)"], ["frontotemporal dementia"]]}
{"id": "5e3a6c49b5b409ea53000017", "question": "Is Verubecestat effective for Alzheimer's Disease?", "answer": "Yes, Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease, as evidenced by the randomized trial conducted by the authors [29719179] The treatment-related adverse events were also associated with the drug [24983746] However, the authors did not mention any insufficient evidence from retrieved abstracts [7510447]", "pmids": ["29719179", "24983746", "7510447"], "pmid_titles": {"29719179": "(No title fetched)", "24983746": "(No title fetched)", "7510447": "Clinical experiences and biochemical findings with tacrine (THA)."}, "topk_used": ["29719179", "29397980", "30970186", "29461065", "31423903", "31387606", "15649697", "33049114", "28749667", "23624169", "20154508", "7579023", "22536363", "7510447", "25871773", "24983746", "23883379", "37943150", "27567808", "37490245"], "topk_titles": {"29719179": "(No title fetched)", "29397980": "(No title fetched)", "30970186": "(No title fetched)", "29461065": "(No title fetched)", "31423903": "(No title fetched)", "31387606": "(No title fetched)", "15649697": "ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.", "33049114": "(No title fetched)", "28749667": "(No title fetched)", "23624169": "(No title fetched)", "20154508": "Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.", "7579023": "One year on tacrine (THA): clinical and biochemical effects in patients with dementia of the Alzheimer type.", "22536363": "Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.", "7510447": "Clinical experiences and biochemical findings with tacrine (THA).", "25871773": "Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A\u03b2 metabolism in apoE4-targeted replacement mice.", "24983746": "(No title fetched)", "23883379": "(No title fetched)", "37943150": "(No title fetched)", "27567808": "(No title fetched)", "37490245": "(No title fetched)"}, "gold_ideal": ["No. Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events."], "gold_exact": ["no"]}
